1Calder PC, Albers R, Antoine JM, et al. (2009) Inflammatory disease processes and interactions with nutrition. Br J Nutr 101, Suppl. 1, S1–45.
2Kolb H & Mandrup-Poulsen T (2010) The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation. Diabetologia 53, 10–20.
3Fernandez-Real JM & Pickup JC (2008) Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab 19, 10–16.
4Herder C, Peltonen M, Koenig W, et al. (2006) Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes 55, 2340–2346.
5Herder C, Illig T, Rathmann W, et al. (2005) Inflammation and type 2 diabetes: results from KORA Augsburg. Gesundheitswesen 67, Suppl. 1, S115–S121.
6Muller S, Martin S, Koenig W, et al. (2002) Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 45, 805–812.
7Kim CS, Park HS, Kawada T, et al. (2006) Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond) 30, 1347–1355.
8Hotamisligil GS, Shargill NS & Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87–91.
9Trayhurn P & Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92, 347–355.
10Tilg H & Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6, 772–783.
11Wellen KE & Hotamisligil GS (2003) Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112, 1785–1788.
12Koerner A, Kratzsch J & Kiess W (2005) Adipocytokines: leptin–the classical, resistin–the controversical, adiponectin–the promising, and more to come. Best Pract Res Clin Endocrinol Metab 19, 525–546.
13Trujillo ME & Scherer PE (2006) Adipose tissue-derived factors: impact on health and disease. Endocr Rev 27, 762–778.
14Stofkova A (2009) Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul 43, 157–168.
15Gil-Campos M, Canete RR & Gil A (2004) Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 23, 963–974.
16Fukuhara A, Matsuda M, Nishizawa M, et al. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307, 426–430.
17McTernan PG, Kusminski CM & Kumar S (2006) Resistin. Curr Opin Lipidol 17, 170–175.
18Yang RZ, Lee MJ, Hu H, et al. (2006) Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 290, E1253–E1261.
19Yang RZ, Lee MJ, Hu H, et al. (2006) Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 3, e287.
20Sethi JK & Vidal-Puig A (2005) Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med 11, 344–347.
21Stephens JM & Vidal-Puig AJ (2006) An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr Opin Lipidol 17, 128–131.
22Juhan-Vague I, Alessi MC, Mavri A, et al. (2003) Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 1, 1575–1579.
23Poitou C, Viguerie N, Cancello R, et al. (2005) Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition. Diabetologia 48, 519–528.
24Somm E, Cettour-Rose P, Asensio C, et al. (2006) Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia 49, 387–393.
25Somm E, Henrichot E, Pernin A, et al. (2005) Decreased fat mass in interleukin-1 receptor antagonist-deficient mice: impact on adipogenesis, food intake, and energy expenditure. Diabetes 54, 3503–3509.
26Meier CA, Bobbioni E, Gabay C, et al. (2002) IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab 87, 1184–1188.
27Netea MG, Joosten LA, Lewis E, et al. (2006) Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med 12, 650–656.
28Skurk T, Kolb H, Muller-Scholze S, et al. (2005) The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. Eur J Endocrinol 152, 863–868.
29Skurk T, berti-Huber C, Herder C, et al. (2007) Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 92, 1023–1033.
30Straczkowski M, Kowalska I, Nikolajuk A, et al. (2007) Increased serum interleukin-18 concentration is associated with hypoadiponectinemia in obesity, independently of insulin resistance. Int J Obes (Lond) 31, 221–225.
31Cancello R, Henegar C, Viguerie N, et al. (2005) Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54, 2277–2286.
32Juge-Aubry CE, Somm E, Pernin A, et al. (2005) Adipose tissue is a regulated source of interleukin-10. Cytokine 29, 270–274.
33Skurk T, Herder C, Kraft I, et al. (2005) Production and release of macrophage migration inhibitory factor from human adipocytes. Endocrinology 146, 1006–1011.
34Straczkowski M, Dzienis-Straczkowska S, Stepien A, et al. (2002) Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J Clin Endocrinol Metab 87, 4602–4606.
35Straczkowski M, Kowalska I, Nikolajuk A, et al. (2003) Plasma interleukin 8 concentrations in obese subjects with impaired glucose tolerance. Cardiovasc Diabetol 2, 5.
36Curat CA, Wegner V, Sengenes C, et al. (2006) Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49, 744–747.
37Herder C, Hauner H, Kempf K, et al. (2007) Constitutive and regulated expression and secretion of interferon-gamma-inducible protein 10 (IP-10/CXCL10) in human adipocytes. Int J Obes (Lond) 31, 403–410.
38Fain JN, Tichansky DS & Madan AK (2005) Transforming growth factor beta1 release by human adipose tissue is enhanced in obesity. Metabolism 54, 1546–1551.
39Gabrielsson BG, Johansson JM, Lonn M, et al. (2003) High expression of complement components in omental adipose tissue in obese men. Obes Res 11, 699–708.
40Guerre-Millo M (2006) Adipose tissue secretory function: implication in metabolic and cardiovascular complications of obesity. J Soc Biol 200, 37–43.
41Graham TE, Yang Q, Bluher M, et al. (2006) Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354, 2552–2563.
42Yang Q, Graham TE, Mody N, et al. (2005) Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436, 356–362.
43Janke J, Engeli S, Boschmann M, et al. (2006) Retinol-binding protein 4 in human obesity. Diabetes 55, 2805–2810.
44Carey VJ, Walters EE, Colditz GA, et al. (1997) Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses’ Health Study. Am J Epidemiol 145, 614–619.
45Kissebah AH, Vydelingum N, Murray R, et al. (1982) Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 54, 254–260.
46Visser M, Bouter LM, McQuillan GM, et al. (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA 282, 2131–2135.
47Cook DG, Mendall MA, Whincup PH, et al. (2000) C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis 149, 139–150.
48Yudkin JS (2003) Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord 27, Suppl. 3, S25–S28.
49Wellen KE & Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115, 1111–1119.
50Despres JP & Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444, 881–887.
51Lafontan M & Girard J (2008) Impact of visceral adipose tissue on liver metabolism. Part I: heterogeneity of adipose tissue and functional properties of visceral adipose tissue. Diabetes Metab 34, 317–327.
52van Harmelen V, Dicker A, Ryden M, et al. (2002) Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes 51, 2029–2036.
53Alessi MC, Bastelica D, Morange P, et al. (2000) Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 49, 1374–1380.
54Bruun JM, Lihn AS, Madan AK, et al. (2004) Higher production of IL-8 in visceral vs. subcutaneous adipose tissue. Implication of nonadipose cells in adipose tissue. Am J Physiol Endocrinol Metab 286, E8–E13.
55Bastelica D, Morange P, Berthet B, et al. (2002) Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 22, 173–178.
56Fain JN, Madan AK, Hiler ML, et al. (2004) Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145, 2273–2282.
57Hauner H (2005) Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc 64, 163–169.
58de Souza Batista CM, Yang RZ, Lee MJ, et al. (2007) Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56, 1655–1661.
59Arner P (2006) Visfatin–a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab 91, 28–30.
60Rabkin SW (2007) Epicardial fat: properties, function and relationship to obesity. Obes Rev 8, 253–261.
61Silaghi A, Piercecchi-Marti MD, Grino M, et al. (2008) Epicardial adipose tissue extent: relationship with age, body fat distribution, and coronaropathy. Obesity (Silver Spring) 16, 2424–2430.
62Jernas M, Palming J, Sjoholm K, et al. (2006) Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression. FASEB J 20, 1540–1542.
63Weyer C, Foley JE, Bogardus C, et al. (2000) Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia 43, 1498–1506.
64Fain JN (2006) Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 74, 443–477.
65Cancello R, Tordjman J, Poitou C, et al. (2006) Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 55, 1554–1561.
66Weisberg SP, McCann D, Desai M, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112, 1796–1808.
67Xu H, Barnes GT, Yang Q, et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112, 1821–1830.
68Henegar C, Tordjman J, Achard V, et al. (2008) Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. Genome Biol 9, R14.
69Kintscher U, Hartge M, Hess K, et al. (2008) T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 28, 1304–1310.
70Rausch ME, Weisberg S, Vardhana P, et al. (2008) Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes (Lond) 32, 451–463.
71Wu H, Ghosh S, Perrard XD, et al. (2007) T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 115, 1029–1038.
72Bornstein SR, Abu-Asab M, Glasow A, et al. (2000) Immunohistochemical and ultrastructural localization of leptin and leptin receptor in human white adipose tissue and differentiating human adipose cells in primary culture. Diabetes 49, 532–538.
73Cousin B, Munoz O, Andre M, et al. (1999) A role for preadipocytes as macrophage-like cells. FASEB J 13, 305–312.
74Cousin B, Andre M, Casteilla L, et al. (2001) Altered macrophage-like functions of preadipocytes in inflammation and genetic obesity. J Cell Physiol 186, 380–386.
75Lumeng CN, Bodzin JL & Saltiel AR (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117, 175–184.
76Olefsky JM & Glass CK (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72, 219–246.
77Karastergiou K & Mohamed-Ali V (2010) The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol 318, 69–78.
78Curat CA, Miranville A, Sengenes C, et al. (2004) From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 53, 1285–1292.
79Guzik TJ, Mangalat D & Korbut R (2006) Adipocytokines – novel link between inflammation and vascular function? J Physiol Pharmacol 57, 505–528.
80Weisberg SP, Hunter D, Huber R, et al. (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116, 115–124.
81Inouye KE, Shi H, Howard JK, et al. (2007) Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 56, 2242–2250.
82Trayhurn P, Wang B & Wood IS (2008) Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br J Nutr 100, 227–235.
83Guerre-Millo M, Grosfeld A & Issad T (2002) Leptin is a hypoxia-inducible gene. Obes Res 10, 856–858.
84Cinti S, Mitchell G, Barbatelli G, et al. (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46, 2347–2355.
85Bouloumie A, Casteilla L & Lafontan M (2008) Adipose tissue lymphocytes and macrophages in obesity and insulin resistance: makers or markers, and which comes first? Arterioscler Thromb Vasc Biol 28, 1211–1213.
86Lagathu C, Bastard JP, Auclair M, et al. (2003) Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 311, 372–379.
87Lacasa D, Taleb S, Keophiphath M, et al. (2007) Macrophage-secreted factors impair human adipogenesis: involvement of proinflammatory state in preadipocytes. Endocrinology 148, 868–877.
88Constant VA, Gagnon A, Landry A, et al. (2006) Macrophage-conditioned medium inhibits the differentiation of 3T3-L1 and human abdominal preadipocytes. Diabetologia 49, 1402–1411.
89Permana PA, Menge C & Reaven PD (2006) Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochem Biophys Res Commun 341, 507–514.
90Suganami T, Nishida J & Ogawa Y (2005) A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 25, 2062–2068.
91Kumar A, Takada Y, Boriek AM, et al. (2004) Nuclear factor-kappaB: its role in health and disease. J Mol Med 82, 434–448.
92Perkins ND (2007) Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8, 49–62.
93Sigal LH (2006) Basic science for the clinician 39: NF-kappaB-function, activation, control, and consequences. J Clin Rheumatol 12, 207–211.
94Maury E & Brichard SM (2010) Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314, 1–16.
95Suganami T, Tanimoto-Koyama K, Nishida J, et al. (2007) Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 27, 84–91.
96Lin Y, Lee H, Berg AH, et al. (2000) The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem 275, 24255–24263.
97Shi H, Kokoeva MV, Inouye K, et al. (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116, 3015–3025.
98Matsuzawa Y (2006) The metabolic syndrome and adipocytokines. FEBS Lett 580, 2917–2921.
99Matsuzawa Y (2006) Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 3, 35–42.
100Chen H (2006) Cellular inflammatory responses: novel insights for obesity and insulin resistance. Pharmacol Res 53, 469–477.
101Malavazos AE, Cereda E, Morricone L, et al. (2005) Monocyte chemoattractant protein 1: a possible link between visceral adipose tissue-associated inflammation and subclinical echocardiographic abnormalities in uncomplicated obesity. Eur J Endocrinol 153, 871–877.
102Malavazos AE, Corsi MM, Ermetici F, et al. (2007) Proinflammatory cytokines and cardiac abnormalities in uncomplicated obesity: relationship with abdominal fat deposition. Nutr Metab Cardiovasc Dis 17, 294–302.
103Ouchi N, Kihara S, Funahashi T, et al. (2003) Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14, 561–566.
104Herder C, Haastert B, Muller-Scholze S, et al. (2005) Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 54, Suppl. 2, S11–S17.
105Stentz FB, Umpierrez GE, Cuervo R, et al. (2004) Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 53, 2079–2086.
106de Luca C & Olefsky JM (2006) Stressed out about obesity and insulin resistance. Nat Med 12, 41–42.
107Harman-Boehm I, Bluher M, Redel H, et al. (2007) Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J Clin Endocrinol Metab 92, 2240–2247.
108Berg AH & Scherer PE (2005) Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96, 939–949.
109Kopelman P (2007) Health risks associated with overweight and obesity. Obes Rev 8, Suppl. 1, 13–17.
110Ziccardi P, Nappo F, Giugliano G, et al. (2002) Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105, 804–809.
111Esposito K, Pontillo A, Di Palo C, et al. (2003) Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289, 1799–1804.
112Heilbronn LK & Clifton PM (2002) C-reactive protein and coronary artery disease: influence of obesity, caloric restriction and weight loss. J Nutr Biochem 13, 316–321.
113Bastard JP, Jardel C, Bruckert E, et al. (2000) Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85, 3338–3342.
114Esposito K, Pontillo A, Ciotola M, et al. (2002) Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab 87, 3864–3866.
115Bastard JP, Vidal H, Jardel C, et al. (2000) Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 gene during very low calorie diet in obese subjects. Int J Obes Relat Metab Disord 24, 70–74.
116Gomez-Ambrosi J, Salvador J, Rotellar F, et al. (2006) Increased serum amyloid A concentrations in morbid obesity decrease after gastric bypass. Obes Surg 16, 262–269.
117Taleb S, Cancello R, Poitou C, et al. (2006) Weight loss reduces adipose tissue cathepsin S and its circulating levels in morbidly obese women. J Clin Endocrinol Metab 91, 1042–1047.
118Laimer M, Kaser S, Kranebitter M, et al. (2005) Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. Int J Obes (Lond) 29, 498–501.
119Kopp CW, Kopp HP, Steiner S, et al. (2003) Weight loss reduces tissue factor in morbidly obese patients. Obes Res 11, 950–956.
120Church TS, Willis MS, Priest EL, et al. (2005) Obesity, macrophage migration inhibitory factor, and weight loss. Int J Obes (Lond) 29, 675–681.
121Christiansen T, Richelsen B & Bruun JM (2005) Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes (Lond) 29, 146–150.
122Vasudevan AR, Wu H, Xydakis AM, et al. (2006) Eotaxin and obesity. J Clin Endocrinol Metab 91, 256–261.
123Krzyzanowska K, Mittermayer F, Krugluger W, et al. (2006) Increase in visfatin after weight loss induced by gastroplastic surgery. Obesity (Silver Spring) 14, 1886–1889.
124Bastard JP, Hainque B, Dusserre E, et al. (1999) Peroxisome proliferator activated receptor-gamma, leptin and tumor necrosis factor-alpha mRNA expression during very low calorie diet in subcutaneous adipose tissue in obese women. Diabetes Metab Res Rev 15, 92–98.
125Kopp HP, Kopp CW, Festa A, et al. (2003) Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 23, 1042–1047.
126Poitou C, Coussieu C, Rouault C, et al. (2006) Serum amyloid A: a marker of adiposity-induced low-grade inflammation but not of metabolic status. Obesity (Silver Spring) 14, 309–318.
127Clement K, Viguerie N, Poitou C, et al. (2004) Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 18, 1657–1669.
128de Luca C & Olefsky JM (2008) Inflammation and insulin resistance. FEBS Lett 582, 97–105.
129Li L, Naples M, Song H, et al. (2007) LCAT-null mice develop improved hepatic insulin sensitivity through altered regulation of transcription factors and suppressors of cytokine signaling. Am J Physiol Endocrinol Metab 293, E587–E594.
130Rui HL, Fan E, Zhou HM, et al. (2002) SUMO-1 modification of the C-terminal KVEKVD of Axin is required for JNK activation but has no effect on Wnt signaling. J Biol Chem 277, 42981–42986.
131Ueki K, Kondo T & Kahn CR (2004) Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24, 5434–5446.
132Kim JH, Kim JE, Liu HY, et al. (2008) Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway. J Biol Chem 283, 708–715.
133Lang CH, Dobrescu C & Bagby GJ (1992) Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130, 43–52.
134Miles PD, Romeo OM, Higo K, et al. (1997) TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 46, 1678–1683.
135Atsumi T, Cho YR, Leng L, et al. (2007) The proinflammatory cytokine macrophage migration inhibitory factor regulates glucose metabolism during systemic inflammation. J Immunol 179, 5399–5406.
136Houstis N, Rosen ED & Lander ES (2006) Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440, 944–948.
137Nishikawa T, Kukidome D, Sonoda K, et al. (2007) Impact of mitochondrial ROS production in the pathogenesis of insulin resistance. Diabetes Res Clin Pract 77, Suppl. 1, S161–S164.
138Li Y, Jiang C, Xu G, et al. (2008) Homocysteine upregulates resistin production from adipocytes in vivo and in vitro. Diabetes 57, 817–827.
139Arner P (2005) Insulin resistance in type 2 diabetes – role of the adipokines. Curr Mol Med 5, 333–339.
140Yan SF, Barile GR, D'Agati V, et al. (2007) The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications. Curr Diab Rep 7, 146–153.
141Nomiyama T, Perez-Tilve D, Ogawa D, et al. (2007) Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest 117, 2877–2888.
142Clement K & Langin D (2007) Regulation of inflammation-related genes in human adipose tissue. J Intern Med 262, 422–430.
143Kim JK, Kim YJ, Fillmore JJ, et al. (2001) Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 108, 437–446.
144Yin MJ, Yamamoto Y & Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396, 77–80.
145Shoelson SE, Lee J & Yuan M (2003) Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord 27, Suppl. 3, S49–S52.
146Fleischman A, Shoelson SE, Bernier R, et al. (2008) Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 31, 289–294.
147Wasko MC, Hubert HB, Lingala VB, et al. (2007) Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 298, 187–193.
148Larsen CM, Faulenbach M, Vaag A, et al. (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356, 1517–1526.
149Barbuio R, Milanski M, Bertolo MB, et al. (2007) Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 194, 539–550.
150Dominguez H, Storgaard H, Rask-Madsen C, et al. (2005) Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 42, 517–525.
151Tam LS, Tomlinson B, Chu TT, et al. (2007) Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 26, 1495–1498.
152Di Rocco P, Manco M, Rosa G, et al. (2004) Lowered tumor necrosis factor receptors, but not increased insulin sensitivity, with infliximab. Obes Res 12, 734–739.
153Borst SE, Lee Y, Conover CF, et al. (2004) Neutralization of tumor necrosis factor-alpha reverses insulin resistance in skeletal muscle but not adipose tissue. Am J Physiol Endocrinol Metab 287, E934–E938.
154Hansen K, Sickelmann F, Pietrowsky R, et al. (1997) Systemic immune changes following meal intake in humans. Am J Physiol 273, R548–R553.
155Plat J, Jellema A, Ramakers J, et al. (2007) Weight loss, but not fish oil consumption, improves fasting and postprandial serum lipids, markers of endothelial function, and inflammatory signatures in moderately obese men. J Nutr 137, 2635–2640.
156Bell DS, O'Keefe JH & Jellinger P (2008) Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? Endocr Pract 14, 112–124.
157O'Keefe JH, Gheewala NM & O'Keefe JO (2008) Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol 51, 249–255.
158Napolitano M & Bravo E (2005) Lipid metabolism and TNF-alpha secretion in response to dietary sterols in human monocyte derived macrophages. Eur J Clin Invest 35, 482–490.
159van Oostrom AJ, Sijmonsma TP, Verseyden C, et al. (2003) Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. J Lipid Res 44, 576–583.
160Luu NT, Madden J, Calder PC, et al. (2007) Dietary supplementation with fish oil modifies the ability of human monocytes to induce an inflammatory response. J Nutr 137, 2769–2774.
161Alipour A, van Oostrom AJ, Izraeljan A, et al. (2008) Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol 28, 792–797.
162Burdge GC & Calder PC (2005) Plasma cytokine response during the postprandial period: a potential causal process in vascular disease? Br J Nutr 93, 3–9.
163Manning PJ, Sutherland WH, McGrath MM, et al. (2008) Postprandial cytokine concentrations and meal composition in obese and lean women. Obesity (Silver Spring) 16, 2046–2052.
164Jellema A, Plat J & Mensink RP (2004) Weight reduction, but not a moderate intake of fish oil, lowers concentrations of inflammatory markers and PAI-1 antigen in obese men during the fasting and postprandial state. Eur J Clin Invest 34, 766–773.
165Esposito K, Ciotola M, Sasso FC, et al. (2007) Effect of a single high-fat meal on endothelial function in patients with the metabolic syndrome: role of tumor necrosis factor-alpha. Nutr Metab Cardiovasc Dis 17, 274–279.
166Nappo F, Esposito K, Cioffi M, et al. (2002) Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 39, 1145–1150.
167Ceriello A, Assaloni R, Da RR, et al. (2005) Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 111, 2518–2524.
168Erridge C, Attina T, Spickett CM, et al. (2007) A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 86, 1286–1292.
169Ceriello A, Bortolotti N, Motz E, et al. (1998) Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care 21, 1529–1533.
170Wellen KE, Fucho R, Gregor MF, et al. (2007) Coordinated regulation of nutrient and inflammatory responses by STAMP2 is essential for metabolic homeostasis. Cell 129, 537–548.
171Abedini A & Shoelson SE (2007) Inflammation and obesity: STAMPing out insulin resistance? Immunol Cell Biol 85, 399–400.
172Candore G, Colonna-Romano G, Balistreri CR, et al. (2006) Biology of longevity: role of the innate immune system. Rejuvenation Res 9, 143–148.
173Krabbe KS, Pedersen M & Bruunsgaard H (2004) Inflammatory mediators in the elderly. Exp Gerontol 39, 687–699.
174Wei J, Xu H, Davies JL, et al. (1992) Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci 51, 1953–1956.
175Hager K, Machein U, Krieger S, et al. (1994) Interleukin-6 and selected plasma proteins in healthy persons of different ages. Neurobiol Aging 15, 771–772.
176Ferrucci L, Corsi A, Lauretani F, et al. (2005) The origins of age-related proinflammatory state. Blood 105, 2294–2299.
177Pedersen M, Bruunsgaard H, Weis N, et al. (2003) Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev 124, 495–502.
178Paolisso G, Rizzo MR, Mazziotti G, et al. (1998) Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol 275, E294–E299.
179Bruunsgaard H, Andersen-Ranberg K, Jeune B, et al. (1999) A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci 54, M357–M364.
180Ballou SP, Lozanski FB, Hodder S, et al. (1996) Quantitative and qualitative alterations of acute-phase proteins in healthy elderly persons. Age Ageing 25, 224–230.
181Roubenoff R, Harris TB, Abad LW, et al. (1998) Monocyte cytokine production in an elderly population: effect of age and inflammation. J Gerontol A Biol Sci Med Sci 53, M20–M26.
182Franceschi C, Capri M, Monti D, et al. (2007) Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 128, 92–105.
183Gangemi S, Pescara L, D'Urbano E, et al. (2005) Aging is characterized by a profound reduction in anti-inflammatory lipoxin A4 levels. Exp Gerontol 40, 612–614.
184Ahluwalia N (2004) Aging, nutrition and immune function. J Nutr Health Aging 8, 2–6.
185Lesourd B (2006) Nutritional factors and immunological ageing. Proc Nutr Soc 65, 319–325.
186Jenny NS, Tracy RP, Ogg MS, et al. (2002) In the elderly, interleukin-6 plasma levels and the − 174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol 22, 2066–2071.
187Bruunsgaard H (2002) Effects of tumor necrosis factor-alpha and interleukin-6 in elderly populations. Eur Cytokine Netw 13, 389–391.
188Nakhai Pour HR, Grobbee DE, Muller M, et al. (2007) Association of endogenous sex hormone with C-reactive protein levels in middle-aged and elderly men. Clin Endocrinol (Oxf) 66, 394–398.
189Guigoz Y, Dore J & Schiffrin EJ (2008) The inflammatory status of old age can be nurtured from the intestinal environment. Curr Opin Clin Nutr Metab Care 11, 13–20.
190Bruunsgaard H, Ladelund S, Pedersen AN, et al. (2003) Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clin Exp Immunol 132, 24–31.
191Harris TB, Ferrucci L, Tracy RP, et al. (1999) Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106, 506–512.
192Reuben DB, Cheh AI, Harris TB, et al. (2002) Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc 50, 638–644.
193Volpato S, Guralnik JM, Ferrucci L, et al. (2001) Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. Circulation 103, 947–953.
194Bruunsgaard H, Pedersen M & Pedersen BK (2001) Aging and proinflammatory cytokines. Curr Opin Hematol 8, 131–136.
195Pate RR, Pratt M, Blair SN, et al. (1995) Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 273, 402–407.
196Caspersen CJ, Powell KE & Christenson GM (1985) Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep 100, 126–131.
197Shephard RJ, Allen C, Benade AJ, et al. (1968) The maximum oxygen intake. An international reference standard of cardiorespiratory fitness. Bull World Health Organ 38, 757–764.
198Hamer M (2007) The relative influences of fitness and fatness on inflammatory factors. Prev Med 44, 3–11.
199Petersen AM & Pedersen BK (2005) The anti-inflammatory effect of exercise. J Appl Physiol 98, 1154–1162.
200Nicklas BJ, You T & Pahor M (2005) Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. CMAJ 172, 1199–1209.
201Kasapis C & Thompson PD (2005) The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol 45, 1563–1569.
202Panagiotakos DB, Kokkinos P, Manios Y, et al. (2004) Physical activity and markers of inflammation and thrombosis related to coronary heart disease. Prev Cardiol 7, 190–194.
203Tomaszewski M, Charchar FJ, Przybycin M, et al. (2003) Strikingly low circulating CRP concentrations in ultramarathon runners independent of markers of adiposity: how low can you go? Arterioscler Thromb Vasc Biol 23, 1640–1644.
204Northoff H, Weinstock C & Berg A (1994) The cytokine response to strenuous exercise. Int J Sports Med 15, Suppl. 3, S167–S171.
205Wärnberg J, Nova E, Romeo J, et al. (2007) Lifestyle-related determinants of inflammation in adolescence. Br J Nutr 98, Suppl. 1, S116–S120.
206Pedersen BK (2006) The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular disease control. Essays Biochem 42, 105–117.
207Pedersen BK, Steensberg A, Fischer C, et al. (2003) Searching for the exercise factor: is IL-6 a candidate? J Muscle Res Cell Motil 24, 113–119.
208Fischer CP, Berntsen A, Perstrup LB, et al. (2007) Plasma levels of interleukin-6 and C-reactive protein are associated with physical inactivity independent of obesity. Scand J Med Sci Sports 17, 580–587.
209Ostrowski K, Rohde T, Zacho M, et al. (1998) Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J Physiol 508, Pt 3, 949–953.
210Fischer CP (2006) Interleukin-6 in acute exercise and training: what is the biological relevance? Exerc Immunol Rev 12, 6–33.
211Fallon KE, Fallon SK & Boston T (2001) The acute phase response and exercise: court and field sports. Br J Sports Med 35, 170–173.
212Mattusch F, Dufaux B, Heine O, et al. (2000) Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. Int J Sports Med 21, 21–24.
213Hammett CJ, Prapavessis H, Baldi JC, et al. (2006) Effects of exercise training on 5 inflammatory markers associated with cardiovascular risk. Am Heart J 151, 367.
214Hammett CJ, Oxenham HC, Baldi JC, et al. (2004) Effect of six months’ exercise training on C-reactive protein levels in healthy elderly subjects. J Am Coll Cardiol 44, 2411–2413.
215Bautmans I, Njemini R, Vasseur S, et al. (2005) Biochemical changes in response to intensive resistance exercise training in the elderly. Gerontology 51, 253–265.
216Nicklas BJ, Ambrosius W, Messier SP, et al. (2004) Diet-induced weight loss, exercise, and chronic inflammation in older, obese adults: a randomized controlled clinical trial. Am J Clin Nutr 79, 544–551.
217Marcell TJ, McAuley KA, Traustadottir T, et al. (2005) Exercise training is not associated with improved levels of C-reactive protein or adiponectin. Metabolism 54, 533–541.
218Fischer CP, Plomgaard P, Hansen AK, et al. (2004) Endurance training reduces the contraction-induced interleukin-6 mRNA expression in human skeletal muscle. Am J Physiol Endocrinol Metab 287, E1189–E1194.
219Kohut ML, McCann DA, Russell DW, et al. (2006) Aerobic exercise, but not flexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6 independent of beta-blockers, BMI, and psychosocial factors in older adults. Brain Behav Immun 20, 201–209.
220Stewart LK, Flynn MG, Campbell WW, et al. (2005) Influence of exercise training and age on CD14+ cell-surface expression of toll-like receptor 2 and 4. Brain Behav Immun 19, 389–397.
221Lakka TA, Lakka HM, Rankinen T, et al. (2005) Effect of exercise training on plasma levels of C-reactive protein in healthy adults: the HERITAGE Family Study. Eur Heart J 26, 2018–2025.
222Pearson TA, Mensah GA, Alexander RW, et al. (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499–511.
223Elosua R, Bartali B, Ordovas JM, et al. (2005) Association between physical activity, physical performance, and inflammatory biomarkers in an elderly population: the InCHIANTI study. J Gerontol A Biol Sci Med Sci 60, 760–767.
224Colbert LH, Visser M, Simonsick EM, et al. (2004) Physical activity, exercise, and inflammatory markers in older adults: findings from the Health, Aging and Body Composition Study. J Am Geriatr Soc 52, 1098–1104.
225Wannamethee SG, Lowe GD, Whincup PH, et al. (2002) Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 105, 1785–1790.
226Reuben DB, Judd-Hamilton L, Harris TB, et al. (2003) The associations between physical activity and inflammatory markers in high-functioning older persons: MacArthur Studies of Successful Aging. J Am Geriatr Soc 51, 1125–1130.
227Geffken DF, Cushman M, Burke GL, et al. (2001) Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol 153, 242–250.
228Taaffe DR, Harris TB, Ferrucci L, et al. (2000) Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging. J Gerontol A Biol Sci Med Sci 55, M709–M715.
229Albert MA, Glynn RJ & Ridker PM (2004) Effect of physical activity on serum C-reactive protein. Am J Cardiol 93, 221–225.
230Jankord R & Jemiolo B (2004) Influence of physical activity on serum IL-6 and IL-10 levels in healthy older men. Med Sci Sports Exerc 36, 960–964.
231Cesari M, Penninx BW, Pahor M, et al. (2004) Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci 59, 242–248.
232Visser M, Pahor M, Taaffe DR, et al. (2002) Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci 57, M326–M332.
233Smith JK, Dykes R, Douglas JE, et al. (1999) Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA 281, 1722–1727.
234Goldhammer E, Tanchilevitch A, Maor I, et al. (2005) Exercise training modulates cytokines activity in coronary heart disease patients. Int J Cardiol 100, 93–99.
235Tisi PV, Hulse M, Chulakadabba A, et al. (1997) Exercise training for intermittent claudication: does it adversely affect biochemical markers of the exercise-induced inflammatory response? Eur J Vasc Endovasc Surg 14, 344–350.
236Milani RV, Lavie CJ & Mehra MR (2004) Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol 43, 1056–1061.
237McGavock JM, Mandic S, Vonder Muhll I, et al. (2004) Low cardiorespiratory fitness is associated with elevated C-reactive protein levels in women with type 2 diabetes. Diabetes Care 27, 320–325.
238Aronson D, Sella R, Sheikh-Ahmad M, et al. (2004) The association between cardiorespiratory fitness and C-reactive protein in subjects with the metabolic syndrome. J Am Coll Cardiol 44, 2003–2007.
239Aronson D, Sheikh-Ahmad M, Avizohar O, et al. (2004) C-Reactive protein is inversely related to physical fitness in middle-aged subjects. Atherosclerosis 176, 173–179.
240Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. (2005) The associations between leisure-time physical activity and inflammatory and coagulation markers related to cardiovascular disease: the ATTICA Study. Prev Med 40, 432–437.
241Abramson JL & Vaccarino V (2002) Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med 162, 1286–1292.
242King DE, Carek P, Mainous AG III, et al. (2003) Inflammatory markers and exercise: differences related to exercise type. Med Sci Sports Exerc 35, 575–581.
243Pischon T, Hankinson SE, Hotamisligil GS, et al. (2003) Leisure-time physical activity and reduced plasma levels of obesity-related inflammatory markers. Obes Res 11, 1055–1064.
244Mora S, Lee IM, Buring JE, et al. (2006) Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA 295, 1412–1419.
245Rawson ES, Freedson PS, Osganian SK, et al. (2003) Body mass index, but not physical activity, is associated with C-reactive protein. Med Sci Sports Exerc 35, 1160–1166.
246Verdaet D, Dendale P, De BD, et al. (2004) Association between leisure time physical activity and markers of chronic inflammation related to coronary heart disease. Atherosclerosis 176, 303–310.
247Raitakari M, Mansikkaniemi K, Marniemi J, et al. (2005) Distribution and determinants of serum high-sensitive C-reactive protein in a population of young adults: The Cardiovascular Risk in Young Finns Study. J Intern Med 258, 428–434.
248Church TS, Barlow CE, Earnest CP, et al. (2002) Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol 22, 1869–1876.
249Church TS, Finley CE, Earnest CP, et al. (2002) Relative associations of fitness and fatness to fibrinogen, white blood cell count, uric acid and metabolic syndrome. Int J Obes Relat Metab Disord 26, 805–813.
250Diaz VA, Player MS, Mainous AG III, et al. (2006) Competing impact of excess weight versus cardiorespiratory fitness on cardiovascular risk. Am J Cardiol 98, 1468–1471.
251Isasi CR, Deckelbaum RJ, Tracy RP, et al. (2003) Physical fitness and C-reactive protein level in children and young adults: the Columbia University BioMarkers Study. Pediatrics 111, 332–338.
252Nemet D, Wang P, Funahashi T, et al. (2003) Adipocytokines, body composition, and fitness in children. Pediatr Res 53, 148–152.
253Halle M, Korsten-Reck U, Wolfarth B, et al. (2004) Low-grade systemic inflammation in overweight children: impact of physical fitness. Exerc Immunol Rev 10, 66–74.
254Kelly AS, Wetzsteon RJ, Kaiser DR, et al. (2004) Inflammation, insulin, and endothelial function in overweight children and adolescents: the role of exercise. J Pediatr 145, 731–736.
255Williams MJ, Milne BJ, Hancox RJ, et al. (2005) C-reactive protein and cardiorespiratory fitness in young adults. Eur J Cardiovasc Prev Rehabil 12, 216–220.
256Platat C, Wagner A, Klumpp T, et al. (2006) Relationships of physical activity with metabolic syndrome features and low-grade inflammation in adolescents. Diabetologia 49, 2078–2085.
257Ruiz JR, Ortega FB & Warnberg J (2007) Associations of low-grade inflammation with physical activity, fitness and fatness in prepubertal children; the European Youth Heart Study. Int J Obes (Lond) 31, 1545–1551.
258Wärnberg J (2006) .
259Thomas NE, Baker JS, Graham MR, et al. (2008) C-reactive protein in schoolchildren and its relation to adiposity, physical activity, aerobic fitness and habitual diet. Br J Sports Med 42, 357–360.
260Ruiz JR, Ortega FB, Warnberg J, et al. (2008) Inflammatory proteins and muscle strength in adolescents: the Avena study. Arch Pediatr Adolesc Med 162, 462–468.
261Dandona P, Aljada A, Chaudhuri A, et al. (2005) Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111, 1448–1454.
262Moeller SM, Reedy J, Millen AE, et al. (2007) Dietary patterns: challenges and opportunities in dietary patterns research an Experimental Biology workshop, April 1, 2006. J Am Diet Assoc 107, 1233–1239.
263Newby PK, Muller D, Hallfrisch J, et al. (2003) Dietary patterns and changes in body mass index and waist circumference in adults. Am J Clin Nutr 77, 1417–1425.
264Michels KB & Schulze MB (2005) Can dietary patterns help us detect diet-disease associations? Nutr Res Rev 18, 241–248.
265Newby PK & Tucker KL (2004) Empirically derived eating patterns using factor or cluster analysis: a review. Nutr Rev 62, 177–203.
266Hu FB (2002) Dietary pattern analysis: a new direction in nutritional epidemiology. Curr Opin Lipidol 13, 3–9.
267Holloszy JO & Fontana L (2007) Caloric restriction in humans. Exp Gerontol 42, 709–712.
268Kolb H & Mandrup-Poulsen T (2005) An immune origin of type 2 diabetes? Diabetologia 48, 1038–1050.
269Johnson JB, Summer W, Cutler RG, et al. (2007) Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma. Free Radic Biol Med 42, 665–674.
270Madsen EL, Rissanen A, Bruun JM, et al. (2008) Weight loss larger than 10 % is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 158, 179–187.
271Guarente L & Picard F (2005) Calorie restriction–the SIR2 connection. Cell 120, 473–482.
272Dali-Youcef N, Lagouge M, Froelich S, et al. (2007) Sirtuins: the ‘magnificent seven’, function, metabolism and longevity. Ann Med 39, 335–345.
273Yamamoto H, Schoonjans K & Auwerx J (2007) Sirtuin functions in health and disease. Mol Endocrinol 21, 1745–1755.
274Salminen A, Ojala J, Huuskonen J, et al. (2008) Interaction of aging-associated signaling cascades: inhibition of NF-kappaB signaling by longevity factors FoxOs and SIRT1. Cell Mol Life Sci 65, 1049–1058.
275Buteau J & Accili D (2007) Regulation of pancreatic beta-cell function by the forkhead protein FoxO1. Diabetes Obes Metab 9, Suppl. 2, 140–146.
276Huang H & Tindall DJ (2007) CDK2 and FOXO1: a fork in the road for cell fate decisions. Cell Cycle 6, 902–906.
277Kim DH, Kim JY, Yu BP, et al. (2008) The activation of NF-kappaB through Akt-induced FOXO1 phosphorylation during aging and its modulation by calorie restriction. Biogerontology 9, 33–47.
278Nakae J, Oki M & Cao Y (2008) The FoxO transcription factors and metabolic regulation. FEBS Lett 582, 54–67.
279Sharman MJ & Volek JS (2004) Weight loss leads to reductions in inflammatory biomarkers after a very-low-carbohydrate diet and a low-fat diet in overweight men. Clin Sci (Lond) 107, 365–369.
280Baur JA, Pearson KJ, Price NL, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337–342.
281Baur JA & Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5, 493–506.
282Dai J, Miller AH, Bremner JD, et al. (2008) Adherence to the Mediterranean diet is inversely associated with circulating interleukin-6 among middle-aged men: a twin study. Circulation 117, 169–175.
283Chrysohoou C, Panagiotakos DB, Pitsavos C, et al. (2004) Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study. J Am Coll Cardiol 44, 152–158.
284Esposito K, Marfella R, Ciotola M, et al. (2004) Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292, 1440–1446.
285Fung TT, McCullough ML, Newby PK, et al. (2005) Diet-quality scores and plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr 82, 163–173.
286Trichopoulou A, Costacou T, Bamia C, et al. (2003) Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 348, 2599–2608.
287Pitsavos C, Panagiotakos DB, Tzima N, et al. (2007) Diet, exercise, and C-reactive protein levels in people with abdominal obesity: the ATTICA epidemiological study. Angiology 58, 225–233.
288Salas-Salvado J, Garcia-Arellano A, Estruch R, et al. (2008) Components of the Mediterranean-type food pattern and serum inflammatory markers among patients at high risk for cardiovascular disease. Eur J Clin Nutr 62, 651–659.
289Ambring A, Johansson M, Axelsen M, et al. (2006) Mediterranean-inspired diet lowers the ratio of serum phospholipid n-6 to n-3 fatty acids, the number of leukocytes and platelets, and vascular endothelial growth factor in healthy subjects. Am J Clin Nutr 83, 575–581.
290Bellido C, Lopez-Miranda J, Perez-Martinez P, et al. (2006) The Mediterranean and CHO diets decrease VCAM-1 and E-selectin expression induced by modified low-density lipoprotein in HUVECs. Nutr Metab Cardiovasc Dis 16, 524–530.
291Esposito K, Ciotola M, Giugliano F, et al. (2006) Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res 18, 405–410.
292Esposito K, Ciotola M, Giugliano F, et al. (2007) Mediterranean diet improves sexual function in women with the metabolic syndrome. Int J Impot Res 19, 486–491.
293Estruch R, Martinez-Gonzalez MA, Corella D, et al. (2006) Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med 145, 1–11.
294Krajcovicova-Kudlackova M & Blazicek P (2005) C-reactive protein and nutrition. Bratisl Lek Listy 106, 345–347.
295Szeto YT, Kwok TC & Benzie IF (2004) Effects of a long-term vegetarian diet on biomarkers of antioxidant status and cardiovascular disease risk. Nutrition 20, 863–866.
296Purschwitz K, Rassoul F, Reuter W, et al. (2001) Soluble leukocyte adhesion molecules in vegetarians of various ages. Z Gerontol Geriatr 34, 476–479.
297Kennedy E, Ohls J, Carlon S, et al. (1994) The Healthy Eating Index Final Report. Alexandria, VA: Food and Nutrition Service, US Department of Agriculture.
298McCullough ML, Feskanich D, Stampfer MJ, et al. (2002) Diet quality and major chronic disease risk in men and women: moving toward improved dietary guidance. Am J Clin Nutr 76, 1261–1271.
299Haines PS, Siega-Riz AM & Popkin BM (1999) The Diet Quality Index revised: a measurement instrument for populations. J Am Diet Assoc 99, 697–704.
300Ford ES, Mokdad AH & Liu S (2005) Healthy Eating Index and C-reactive protein concentration: findings from the National Health and Nutrition Examination Survey III, 1988–1994. Eur J Clin Nutr 59, 278–283.
301Fargnoli JL, Fung TT, Olenczuk DM, et al. (2008) Adherence to healthy eating patterns is associated with higher circulating total and high-molecular-weight adiponectin and lower resistin concentrations in women from the Nurses’ Health Study. Am J Clin Nutr 88, 1213–1224.
302Boynton A, Neuhouser ML, Wener MH, et al. (2007) Associations between healthy eating patterns and immune function or inflammation in overweight or obese postmenopausal women. Am J Clin Nutr 86, 1445–1455.
303Lopez-Garcia E, Schulze MB, Fung TT, et al. (2004) Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr 80, 1029–1035.
304Schulze MB, Hoffmann K, Manson JE, et al. (2005) Dietary pattern, inflammation, and incidence of type 2 diabetes in women. Am J Clin Nutr 82, 675–684.
305Hoebeeck LI, Rietzschel ER, Langlois M, et al. (2011) The relationship between diet and subclinical atherosclerosis: results from the Asklepios Study. Eur J Clin Nutr 65, 606–613.
306Nettleton JA, Steffen LM, Mayer-Davis EJ, et al. (2006) Dietary patterns are associated with biochemical markers of inflammation and endothelial activation in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Clin Nutr 83, 1369–1379.
307Esmaillzadeh A, Kimiagar M, Mehrabi Y, et al. (2007) Dietary patterns and markers of systemic inflammation among Iranian women. J Nutr 137, 992–998.
308Nanri A, Yoshida D, Yamaji T, et al. (2008) Dietary patterns and C-reactive protein in Japanese men and women. Am J Clin Nutr 87, 1488–1496.
309Nettleton JA, Matijevic N, Follis JL, et al. (2010) Associations between dietary patterns and flow cytometry-measured biomarkers of inflammation and cellular activation in the Atherosclerosis Risk in Communities (ARIC) Carotid Artery MRI Study. Atherosclerosis 212, 260–267.
310Jensen MK, Koh-Banerjee P, Franz M, et al. (2006) Whole grains, bran, and germ in relation to homocysteine and markers of glycemic control, lipids, and inflammation 1. Am J Clin Nutr 83, 275–283.
311Lutsey PL, Jacobs DR Jr, Kori S, et al. (2007) Whole grain intake and its cross-sectional association with obesity, insulin resistance, inflammation, diabetes and subclinical CVD: The MESA Study. Br J Nutr 98, 397–405.
312Mantzoros CS, Williams CJ, Manson JE, et al. (2006) Adherence to the Mediterranean dietary pattern is positively associated with plasma adiponectin concentrations in diabetic women. Am J Clin Nutr 84, 328–335.
313Masters RC, Liese AD, Haffner SM, et al. (2010) Whole and refined grain intakes are related to inflammatory protein concentrations in human plasma. J Nutr 140, 587–594.
314Qi L, van Dam RM, Liu S, et al. (2006) Whole-grain, bran, and cereal fiber intakes and markers of systemic inflammation in diabetic women. Diabetes Care 29, 207–211.
315Qi L, Rimm E, Liu S, et al. (2005) Dietary glycemic index, glycemic load, cereal fiber, and plasma adiponectin concentration in diabetic men. Diabetes Care 28, 1022–1028.
316Andersson A, Tengblad S, Karlstrom B, et al. (2007) Whole-grain foods do not affect insulin sensitivity or markers of lipid peroxidation and inflammation in healthy, moderately overweight subjects. J Nutr 137, 1401–1407.
317Brownlee IA, Moore C, Chatfield M, et al. (2010) Markers of cardiovascular risk are not changed by increased whole-grain intake: the WHOLEheart study, a randomised, controlled dietary intervention. Br J Nutr 104, 125–134.
318Esposito K, Nappo F, Giugliano F, et al. (2003) Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. Am J Clin Nutr 78, 1135–1140.
319Katcher HI, Legro RS, Kunselman AR, et al. (2008) The effects of a whole grain-enriched hypocaloric diet on cardiovascular disease risk factors in men and women with metabolic syndrome. Am J Clin Nutr 87, 79–90.
320Tighe P, Duthie G, Vaughan N, et al. (2010) Effect of increased consumption of whole-grain foods on blood pressure and other cardiovascular risk markers in healthy middle-aged persons: a randomized controlled trial. Am J Clin Nutr 92, 733–740.
321Mateo AN, Aura AM, Selinheimo E, et al. (2011) Bioprocessing of wheat bran in whole wheat bread increases the bioavailability of phenolic acids in men and exerts antiinflammatory effects ex vivo. J Nutr 141, 137–143.
322Bhupathiraju SN & Tucker KL (2011) Greater variety in fruit and vegetable intake is associated with lower inflammation in Puerto Rican adults. Am J Clin Nutr 93, 37–46.
323Chun OK, Chung SJ, Claycombe KJ, et al. (2008) Serum C-reactive protein concentrations are inversely associated with dietary flavonoid intake in U.S. adults. J Nutr 138, 753–760.
324Esmaillzadeh A, Kimiagar M, Mehrabi Y, et al. (2006) Fruit and vegetable intakes, C-reactive protein, and the metabolic syndrome. Am J Clin Nutr 84, 1489–1497.
325Gao X, Bermudez OI & Tucker KL (2004) Plasma C-reactive protein and homocysteine concentrations are related to frequent fruit and vegetable intake in Hispanic and non-Hispanic white elders. J Nutr 134, 913–918.
326Hermsdorff HH, Zulet MA, Puchau B, et al. (2010) Fruit and vegetable consumption and proinflammatory gene expression from peripheral blood mononuclear cells in young adults: a translational study. Nutr Metab (Lond) 7, 42.
327Holt EM, Steffen LM, Moran A, et al. (2009) Fruit and vegetable consumption and its relation to markers of inflammation and oxidative stress in adolescents. J Am Diet Assoc 109, 414–421.
328Oliveira A, Rodriguez-Artalejo F & Lopes C (2009) The association of fruits, vegetables, antioxidant vitamins and fibre intake with high-sensitivity C-reactive protein: sex and body mass index interactions. Eur J Clin Nutr 63, 1345–1352.
329Wannamethee SG, Lowe GD, Rumley A, et al. (2006) Associations of vitamin C status, fruit and vegetable intakes, and markers of inflammation and hemostasis. Am J Clin Nutr 83, 567–574.
330Yannakoulia M, Yiannakouris N, Melistas L, et al. (2008) Dietary factors associated with plasma high molecular weight and total adiponectin levels in apparently healthy women. Eur J Endocrinol 159, R5–R10.
331Basu A, Du M, Leyva MJ, et al. (2010) Blueberries decrease cardiovascular risk factors in obese men and women with metabolic syndrome. J Nutr 140, 1582–1587.
332Castilla P, Echarri R, Davalos A, et al. (2006) Concentrated red grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects. Am J Clin Nutr 84, 252–262.
333Curtis PJ, Kroon PA, Hollands WJ, et al. (2009) Cardiovascular disease risk biomarkers and liver and kidney function are not altered in postmenopausal women after ingesting an elderberry extract rich in anthocyanins for 12 weeks. J Nutr 139, 2266–2271.
334Dalgard C, Nielsen F, Morrow JD, et al. (2009) Supplementation with orange and blackcurrant juice, but not vitamin E, improves inflammatory markers in patients with peripheral arterial disease. Br J Nutr 101, 263–269.
335Esposito K, Nappo F, Giugliano F, et al. (2003) Effect of dietary antioxidants on postprandial endothelial dysfunction induced by a high-fat meal in healthy subjects. Am J Clin Nutr 77, 139–143.
336Freese R, Vaarala O, Turpeinen AM, et al. (2004) No difference in platelet activation or inflammation markers after diets rich or poor in vegetables, berries and apple in healthy subjects. Eur J Nutr 43, 175–182.
337Karlsen A, Retterstol L, Laake P, et al. (2007) Anthocyanins inhibit nuclear factor-kappaB activation in monocytes and reduce plasma concentrations of pro-inflammatory mediators in healthy adults. J Nutr 137, 1951–1954.
338Karlsen A, Paur I, Bohn SK, et al. (2010) Bilberry juice modulates plasma concentration of NF-kappaB related inflammatory markers in subjects at increased risk of CVD. Eur J Nutr 49, 345–355.
339Kelley DS, Rasooly R, Jacob RA, et al. (2006) Consumption of Bing sweet cherries lowers circulating concentrations of inflammation markers in healthy men and women. J Nutr 136, 981–986.
340Larmo P, Alin J, Salminen E, et al. (2008) Effects of sea buckthorn berries on infections and inflammation: a double-blind, randomized, placebo-controlled trial. Eur J Clin Nutr 62, 1123–1130.
341Morand C, Dubray C, Milenkovic D, et al. (2011) Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers. Am J Clin Nutr 93, 73–80.
342Sanchez-Moreno C, Cano MP, de AB, et al. (2004) Consumption of high-pressurized vegetable soup increases plasma vitamin C and decreases oxidative stress and inflammatory biomarkers in healthy humans. J Nutr 134, 3021–3025.
343Sanchez-Moreno C, Cano MP, de AB, et al. (2003) High-pressurized orange juice consumption affects plasma vitamin C, antioxidative status and inflammatory markers in healthy humans. J Nutr 133, 2204–2209.
344van Doorn MB, Espirito Santo SM, Meijer P, et al. (2006) Effect of garlic powder on C-reactive protein and plasma lipids in overweight and smoking subjects. Am J Clin Nutr 84, 1324–1329.
345Watzl B, Kulling SE, Moseneder J, et al. (2005) A 4-wk intervention with high intake of carotenoid-rich vegetables and fruit reduces plasma C-reactive protein in healthy, nonsmoking men. Am J Clin Nutr 82, 1052–1058.
346Zern TL, Wood RJ, Greene C, et al. (2005) Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J Nutr 135, 1911–1917.
347Azadbakht L, Kimiagar M, Mehrabi Y, et al. (2007) Soy consumption, markers of inflammation, and endothelial function: a cross-over study in postmenopausal women with the metabolic syndrome. Diabetes Care 30, 967–973.
348Azadbakht L, Atabak S & Esmaillzadeh A (2008) Soy protein intake, cardiorenal indices, and C-reactive protein in type 2 diabetes with nephropathy: a longitudinal randomized clinical trial. Diabetes Care 31, 648–654.
349Beavers KM, Serra MC, Beavers DP, et al. (2010) Soy and the exercise-induced inflammatory response in postmenopausal women. Appl Physiol Nutr Metab 35, 261–269.
350Beavers KM, Serra MC, Beavers DP, et al. (2009) Soymilk supplementation does not alter plasma markers of inflammation and oxidative stress in postmenopausal women. Nutr Res 29, 616–622.
351Blum A, Lang N, Peleg A, et al. (2003) Effects of oral soy protein on markers of inflammation in postmenopausal women with mild hypercholesterolemia. Am Heart J 145, e7.
352Charles C, Yuskavage J, Carlson O, et al. (2009) Effects of high-dose isoflavones on metabolic and inflammatory markers in healthy postmenopausal women. Menopause 16, 395–400.
353Greany KA, Nettleton JA, Wangen KE, et al. (2008) Consumption of isoflavone-rich soy protein does not alter homocysteine or markers of inflammation in postmenopausal women. Eur J Clin Nutr 62, 1419–1425.
354Hanson LN, Engelman HM, Alekel DL, et al. (2006) Effects of soy isoflavones and phytate on homocysteine, C-reactive protein, and iron status in postmenopausal women. Am J Clin Nutr 84, 774–780.
355Hilpert KF, Kris-Etherton PM & West SG (2005) Lipid response to a low-fat diet with or without soy is modified by C-reactive protein status in moderately hypercholesterolemic adults. J Nutr 135, 1075–1079.
356Jenkins DJ, Kendall CW, Jackson CJ, et al. (2002) Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women. Am J Clin Nutr 76, 365–372.
357Maskarinec G, Steude JS, Franke AA, et al. (2009) Inflammatory markers in a 2-year soy intervention among premenopausal women. J Inflamm (Lond) 6, 9.
358Matthan NR, Jalbert SM, Ausman LM, et al. (2007) Effect of soy protein from differently processed products on cardiovascular disease risk factors and vascular endothelial function in hypercholesterolemic subjects. Am J Clin Nutr 85, 960–966.
359McVeigh BL, Dillingham BL, Lampe JW, et al. (2006) Effect of soy protein varying in isoflavone content on serum lipids in healthy young men. Am J Clin Nutr 83, 244–251.
360Mukuddem-Petersen J, Stonehouse OW, Jerling JC, et al. (2007) Effects of a high walnut and high cashew nut diet on selected markers of the metabolic syndrome: a controlled feeding trial. Br J Nutr 97, 1144–1153.
361Nasca MM, Zhou JR & Welty FK (2008) Effect of soy nuts on adhesion molecules and markers of inflammation in hypertensive and normotensive postmenopausal women. Am J Cardiol 102, 84–86.
362Ryan-Borchers TA, Park JS, Chew BP, et al. (2006) Soy isoflavones modulate immune function in healthy postmenopausal women. Am J Clin Nutr 83, 1118–1125.
363Teede HJ, Dalais FS & McGrath BP (2004) Dietary soy containing phytoestrogens does not have detectable estrogenic effects on hepatic protein synthesis in postmenopausal women. Am J Clin Nutr 79, 396–401.
364Zemel MB, Sun X, Sobhani T, et al. (2010) Effects of dairy compared with soy on oxidative and inflammatory stress in overweight and obese subjects. Am J Clin Nutr 91, 16–22.
365Maskarinec G, Oum R, Chaptman AK, et al. (2009) Inflammatory markers in a randomised soya intervention among men. Br J Nutr 101, 1740–1744.
366Napora JK, Short RG, Muller DC, et al. (2011) High-dose isoflavones do not improve metabolic and inflammatory parameters in androgen-deprived men with prostate cancer. J Androl 32, 40–48.
367Jiang R, Jacobs DR Jr, Mayer-Davis E, et al. (2006) Nut and seed consumption and inflammatory markers in the multi-ethnic study of atherosclerosis. Am J Epidemiol 163, 222–231.
368Li TY, Brennan AM, Wedick NM, et al. (2009) Regular consumption of nuts is associated with a lower risk of cardiovascular disease in women with type 2 diabetes. J Nutr 139, 1333–1338.
369Sari I, Baltaci Y, Bagci C, et al. (2010) Effect of pistachio diet on lipid parameters, endothelial function, inflammation, and oxidative status: a prospective study. Nutrition 26, 399–404.
370Rajaram S, Connell KM & Sabate J (2010) Effect of almond-enriched high-monounsaturated fat diet on selected markers of inflammation: a randomised, controlled, crossover study. Br J Nutr 103, 907–912.
371Banel DK & Hu FB (2009) Effects of walnut consumption on blood lipids and other cardiovascular risk factors: a meta-analysis and systematic review. Am J Clin Nutr 90, 56–63.
372Ros E (2009) Nuts and novel biomarkers of cardiovascular disease. Am J Clin Nutr 89, 1649S–1656S.
373Lopez-Garcia E, Schulze MB, Manson JE, et al. (2004) Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. J Nutr 134, 1806–1811.
374Madsen T, Skou HA, Hansen VE, et al. (2001) C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. Am J Cardiol 88, 1139–1142.
375King DE, Egan BM & Geesey ME (2003) Relation of dietary fat and fiber to elevation of C-reactive protein. Am J Cardiol 92, 1335–1339.
376Hickling S, Hung J, Knuiman M, et al. (2008) Are the associations between diet and C-reactive protein independent of obesity? Prev Med 47, 71–76.
377Zampelas A, Panagiotakos DB, Pitsavos C, et al. (2005) Fish consumption among healthy adults is associated with decreased levels of inflammatory markers related to cardiovascular disease: the ATTICA study. J Am Coll Cardiol 46, 120–124.
378Lindqvist H, Langkilde AM, Undeland I, et al. (2007) Herring (Clupea harengus) supplemented diet influences risk factors for CVD in overweight subjects. Eur J Clin Nutr 61, 1106–1113.
379Maki T, Pham NM, Yoshida D, et al. (2010) The relationship of coffee and green tea consumption with high-sensitivity C-reactive protein in Japanese men and women. Clin Chem Lab Med 48, 849–854.
380De Bacquer D, Clays E, Delanghe J, et al. (2006) Epidemiological evidence for an association between habitual tea consumption and markers of chronic inflammation. Atherosclerosis 189, 428–435.
381Basu A, Du M, Sanchez K, et al. (2011) Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome. Nutrition 27, 206–213.
382de Maat MP, Pijl H, Kluft C, et al. (2000) Consumption of black and green tea had no effect on inflammation, haemostasis and endothelial markers in smoking healthy individuals. Eur J Clin Nutr 54, 757–763.
383Fukino Y, Ikeda A, Maruyama K, et al. (2008) Randomized controlled trial for an effect of green tea-extract powder supplementation on glucose abnormalities. Eur J Clin Nutr 62, 953–960.
384Hodgson JM, Puddey IB, Mori TA, et al. (2001) Effects of regular ingestion of black tea on haemostasis and cell adhesion molecules in humans. Eur J Clin Nutr 55, 881–886.
385Mukamal KJ, MacDermott K, Vinson JA, et al. (2007) A 6-month randomized pilot study of black tea and cardiovascular risk factors. Am Heart J 154, 724–726.
386Ryu OH, Lee J, Lee KW, et al. (2006) Effects of green tea consumption on inflammation, insulin resistance and pulse wave velocity in type 2 diabetes patients. Diabetes Res Clin Pract 71, 356–358.
387Steptoe A, Gibson EL, Vuononvirta R, et al. (2007) The effects of chronic tea intake on platelet activation and inflammation: a double-blind placebo controlled trial. Atherosclerosis 193, 277–282.
388Sung H, Min WK, Lee W, et al. (2005) The effects of green tea ingestion over four weeks on atherosclerotic markers. Ann Clin Biochem 42, 292–297.
389Widlansky ME, Duffy SJ, Hamburg NM, et al. (2005) Effects of black tea consumption on plasma catechins and markers of oxidative stress and inflammation in patients with coronary artery disease. Free Radic Biol Med 38, 499–506.
390Khan N, Afaq F, Saleem M, et al. (2006) Targeting multiple signaling pathways by green tea polyphenol ( − )-epigallocatechin-3-gallate. Cancer Res 66, 2500–2505.
391Kim SJ, Jeong HJ, Lee KM, et al. (2007) Epigallocatechin-3-gallate suppresses NF-kappaB activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells. J Nutr Biochem 18, 587–596.
392Syed DN, Afaq F, Kweon MH, et al. (2007) Green tea polyphenol EGCG suppresses cigarette smoke condensate-induced NF-kappaB activation in normal human bronchial epithelial cells. Oncogene 26, 673–682.
393Feng WY (2006) Metabolism of green tea catechins: an overview. Curr Drug Metab 7, 755–809.
394Renouf M, Guy P, Marmet C, et al. (2010) Plasma appearance and correlation between coffee and green tea metabolites in human subjects. Br J Nutr 104, 1635–1640.
395Hamer M, Williams ED, Vuononvirta R, et al. (2006) Association between coffee consumption and markers of inflammation and cardiovascular function during mental stress. J Hypertens 24, 2191–2197.
396Lopez-Garcia E, van Dam RM, Qi L, et al. (2006) Coffee consumption and markers of inflammation and endothelial dysfunction in healthy and diabetic women. Am J Clin Nutr 84, 888–893.
397Williams CJ, Fargnoli JL, Hwang JJ, et al. (2008) Coffee consumption is associated with higher plasma adiponectin concentrations in women with or without type 2 diabetes: a prospective cohort study. Diabetes Care 31, 504–507.
398Zampelas A, Panagiotakos DB, Pitsavos C, et al. (2004) Associations between coffee consumption and inflammatory markers in healthy persons: the ATTICA study. Am J Clin Nutr 80, 862–867.
399Rodrigues IM & Klein LC (2006) Boiled or filtered coffee? Effects of coffee and caffeine on cholesterol, fibrinogen and C-reactive protein. Toxicol Rev 25, 55–69.
400Bonita JS, Mandarano M, Shuta D, et al. (2007) Coffee and cardiovascular disease: in vitro, cellular, animal, and human studies. Pharmacol Res 55, 187–198.
401Moisey LL, Kacker S, Bickerton AC, et al. (2008) Caffeinated coffee consumption impairs blood glucose homeostasis in response to high and low glycemic index meals in healthy men. Am J Clin Nutr 87, 1254–1261.
402Lane JD, Feinglos MN & Surwit RS (2008) Caffeine increases ambulatory glucose and postprandial responses in coffee drinkers with type 2 diabetes. Diabetes Care 31, 221–222.
403Battram DS, Arthur R, Weekes A, et al. (2006) The glucose intolerance induced by caffeinated coffee ingestion is less pronounced than that due to alkaloid caffeine in men. J Nutr 136, 1276–1280.
404Kempf K, Herder C, Erlund I, et al. (2010) Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. Am J Clin Nutr 91, 950–957.
405Adamson GE, Lazarus SA, Mitchell AE, et al. (1999) HPLC method for the quantification of procyanidins in cocoa and chocolate samples and correlation to total antioxidant capacity. J Agric Food Chem 47, 4184–4188.
406Hammerstone JF, Lazarus SA, Mitchell AE, et al. (1999) Identification of procyanidins in cocoa (Theobroma cacao) and chocolate using high-performance liquid chromatography/mass spectrometry. J Agric Food Chem 47, 490–496.
407Natsume M, Osakabe N, Yamagishi M, et al. (2000) Analyses of polyphenols in cacao liquor, cocoa, and chocolate by normal-phase and reversed-phase HPLC. Biosci Biotechnol Biochem 64, 2581–2587.
408Lazarus SA, Adamson GE, Hammerstone JF, et al. (1999) High-performance liquid chromatography/mass spectrometry analysis of proanthocyanidins in foods and beverages. J Agric Food Chem 47, 3693–3701.
409Lazarus SA, Hammerstone JF & Schmitz HH (1999) Chocolate contains additional flavonoids not found in tea. Lancet 354, 1825.
410Vinson JA, Jang J, Dabbagh YA, et al. (1995) Plant polyphenols exhibit lipo-protein bound antioxidant activity using an in vitro oxidation model for heart disease. J Agric Food Chem 43, 2798–2799.
411Hammerstone JF, Lazarus SA & Schmitz HH (2000) Procyanidin content and variation in some commonly consumed foods. J Nutr 130, 2086S–2092S.
412Mao T, Van de Water J, Keen CL, et al. (2000) Cocoa procyanidins and human cytokine transcription and secretion. J Nutr 130, 2093S–2099S.
413Mao TK, Powell J, Van de Water J, et al. (2000) The effect of cocoa procyanidins on the transcription and secretion of interleukin 1 beta in peripheral blood mononuclear cells. Life Sci 66, 1377–1386.
414di Giuseppe R, Di Castelnuovo A, Centritto F, et al. (2008) Regular consumption of dark chocolate is associated with low serum concentrations of C-reactive protein in a healthy Italian population. J Nutr 138, 1939–1945.
415Mathur S, Devaraj S, Grundy SM, et al. (2002) Cocoa products decrease low density lipoprotein oxidative susceptibility but do not affect biomarkers of inflammation in humans. J Nutr 132, 3663–3667.
416Hamed MS, Gambert S, Bliden KP, et al. (2008) Dark chocolate effect on platelet activity, C-reactive protein and lipid profile: a pilot study. South Med J 101, 1203–1208.
417Monagas M, Khan N, Andres-Lacueva C, et al. (2009) Effect of cocoa powder on the modulation of inflammatory biomarkers in patients at high risk of cardiovascular disease. Am J Clin Nutr 90, 1144–1150.
418Albert MA, Glynn RJ & Ridker PM (2003) Alcohol consumption and plasma concentration of C-reactive protein. Circulation 107, 443–447.
419Alho H, Sillanaukee P, Kalela A, et al. (2004) Alcohol misuse increases serum antibodies to oxidized LDL and C-reactive protein. Alcohol Alcohol 39, 312–315.
420Averina M, Nilssen O, Arkhipovsky VL, et al. (2006) C-reactive protein and alcohol consumption: Is there a U-shaped association? Results from a population-based study in Russia. The Arkhangelsk study. Atherosclerosis 188, 309–315.
421Bermudez EA, Rifai N, Buring J, et al. (2002) Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 22, 1668–1673.
422Englund OL, Brohall G, Behre CJ, et al. (2006) Alcohol consumption in relation to metabolic regulation, inflammation, and adiponectin in 64-year-old Caucasian women: a population-based study with a focus on impaired glucose regulation. Diabetes Care 29, 908–913.
423Gonzalez-Quintela A, Alende R, Gude F, et al. (2008) Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol 151, 42–50.
424Hoffmeister A, Imhof A, Rothenbacher D, et al. (2003) Moderate alcohol consumption and plasma concentration of sensitive markers of inflammation. Comment on an atheroprotective relationship. Dtsch Med Wochenschr 128, 2237–2241.
425Imhof A, Froehlich M, Brenner H, et al. (2001) Effect of alcohol consumption on systemic markers of inflammation. Lancet 357, 763–767.
426Imhof A, Woodward M, Doering A, et al. (2004) Overall alcohol intake, beer, wine, and systemic markers of inflammation in western Europe: results from three MONICA samples (Augsburg, Glasgow, Lille). Eur Heart J 25, 2092–2100.
427Mukamal KJ, Cushman M, Mittleman MA, et al. (2004) Alcohol consumption and inflammatory markers in older adults: the Cardiovascular Health Study. Atherosclerosis 173, 79–87.
428Pai JK, Hankinson SE, Thadhani R, et al. (2006) Moderate alcohol consumption and lower levels of inflammatory markers in US men and women. Atherosclerosis 186, 113–120.
429Shai I, Rimm EB, Schulze MB, et al. (2004) Moderate alcohol intake and markers of inflammation and endothelial dysfunction among diabetic men. Diabetologia 47, 1760–1767.
430Stewart SH, Mainous AG III & Gilbert G (2002) Relation between alcohol consumption and C-reactive protein levels in the adult US population. J Am Board Fam Pract 15, 437–442.
431Volpato S, Pahor M, Ferrucci L, et al. (2004) Relationship of alcohol intake with inflammatory markers and plasminogen activator inhibitor-1 in well-functioning older adults: the Health, Aging, and Body Composition study. Circulation 109, 607–612.
432Wannamethee SG, Lowe GD, Shaper G, et al. (2003) The effects of different alcoholic drinks on lipids, insulin and haemostatic and inflammatory markers in older men. Thromb Haemost 90, 1080–1087.
433Beulens JW, de Zoete EC, Kok FJ, et al. (2008) Effect of moderate alcohol consumption on adipokines and insulin sensitivity in lean and overweight men: a diet intervention study. Eur J Clin Nutr 62, 1098–1105.
434Beulens JW, van den BR, Kok FJ, et al. (2008) Moderate alcohol consumption and lipoprotein-associated phospholipase A2 activity. Nutr Metab Cardiovasc Dis 18, 539–544.
435Watzl B, Bub A, Briviba K, et al. (2002) Acute intake of moderate amounts of red wine or alcohol has no effect on the immune system of healthy men. Eur J Nutr 41, 264–270.
436Watzl B, Bub A, Pretzer G, et al. (2004) Daily moderate amounts of red wine or alcohol have no effect on the immune system of healthy men. Eur J Clin Nutr 58, 40–45.
437Beulens JW, van Beers RM, Stolk RP, et al. (2006) The effect of moderate alcohol consumption on fat distribution and adipocytokines. Obesity (Silver Spring) 14, 60–66.
438Blanco-Colio LM, Valderrama M, Alvarez-Sala LA, et al. (2000) Red wine intake prevents nuclear factor-kappaB activation in peripheral blood mononuclear cells of healthy volunteers during postprandial lipemia. Circulation 102, 1020–1026.
439Blann AD, Williams NR, Lip GY, et al. (2002) Acute ingestion of red wine by men activates platelets but does not influence endothelial markers: no effect of white wine. Blood Coagul Fibrinolysis 13, 647–651.
440Dhindsa S, Tripathy D, Mohanty P, et al. (2004) Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factor-kappaB in mononuclear cells. Metabolism 53, 330–334.
441Gonzalez-Quintela A, Dominguez-Santalla MJ, Perez LF, et al. (2000) Influence of acute alcohol intake and alcohol withdrawal on circulating levels of IL-6, IL-8, IL-10 and IL-12. Cytokine 12, 1437–1440.
442Greenfield JR, Samaras K, Hayward CS, et al. (2005) Beneficial postprandial effect of a small amount of alcohol on diabetes and cardiovascular risk factors: modification by insulin resistance. J Clin Endocrinol Metab 90, 661–672.
443Pedersen N, Larsen S, Seidelin JB, et al. (2004) Alcohol modulates circulating levels of interleukin-6 and monocyte chemoattractant protein-1 in chronic pancreatitis. Scand J Gastroenterol 39, 277–282.
444Retterstol L, Berge KE, Braaten O, et al. (2005) A daily glass of red wine: does it affect markers of inflammation? Alcohol 40, 102–105.
445Sacanella E, Vazquez-Agell M, Mena MP, et al. (2007) Down-regulation of adhesion molecules and other inflammatory biomarkers after moderate wine consumption in healthy women: a randomized trial. Am J Clin Nutr 86, 1463–1469.
446Sierksma A, van der Gaag MS, Kluft C, et al. (2002) Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels; a randomized, diet-controlled intervention study. Eur J Clin Nutr 56, 1130–1136.
447Vazquez-Agell M, Sacanella E, Tobias E, et al. (2007) Inflammatory markers of atherosclerosis are decreased after moderate consumption of cava (sparkling wine) in men with low cardiovascular risk. J Nutr 137, 2279–2284.
448Williams MJ, Sutherland WH, Whelan AP, et al. (2004) Acute effect of drinking red and white wines on circulating levels of inflammation-sensitive molecules in men with coronary artery disease. Metabolism 53, 318–323.
449Vlassara H (2005) Advanced glycation in health and disease: role of the modern environment. Ann N Y Acad Sci 1043, 452–460.
450Vlassara H & Striker G (2007) Glycotoxins in the diet promote diabetes and diabetic complications. Curr Diab Rep 7, 235–241.
451Ames JM (2007) Evidence against dietary advanced glycation endproducts being a risk to human health. Mol Nutr Food Res 51, 1085–1090.
452Henle T (2007) Dietary advanced glycation end products – a risk to human health? A call for an interdisciplinary debate. Mol Nutr Food Res 51, 1075–1078.
453Sebekova K & Somoza V (2007) Dietary advanced glycation endproducts (AGEs) and their health effects–PRO. Mol Nutr Food Res 51, 1079–1084.
454Henle T (2003) AGEs in foods: do they play a role in uremia? Kidney Int Suppl 63, S145–S147.
455Monnier VM (2003) Intervention against the Maillard reaction in vivo. Arch Biochem Biophys 419, 1–15.
456Koschinsky T, He CJ, Mitsuhashi T, et al. (1997) Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 94, 6474–6479.
457Sebekova K, Podracka L, Heidland A, et al. (2001) Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation – are they inter-related? Clin Nephrol 56, S21–S26.
458Thornalley PJ (2005) Glycation free adduct accumulation in renal disease: the new AGE. Pediatr Nephrol 20, 1515–1522.
459Uribarri J, Peppa M, Cai W, et al. (2003) Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis 42, 532–538.
460Baynes JW & Thorpe SR (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48, 1–9.
461Goldberg T, Cai W, Peppa M, et al. (2004) Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 104, 1287–1291.
462Cerami C, Founds H, Nicholl I, et al. (1997) Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A 94, 13915–13920.
463Erbersdobler HF & Faist V (2001) Metabolic transit of Amadori products. Nahrung 45, 177–181.
464Bergmann R, Helling R, Heichert C, et al. (2001) Radio fluorination and positron emission tomography (PET) as a new approach to study the in vivo distribution and elimination of the advanced glycation endproducts N epsilon-carboxymethyllysine (CML) and N epsilon-carboxyethyllysine (CEL). Nahrung 45, 182–188.
465Finot PA & Magnenat E (1981) Metabolic transit of early and advanced Maillard products. Prog Food Nutr Sci 5, 193–207.
466Ahmed N (2005) Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract 67, 3–21.
467Hidalgo FJ & Zamora R (2005) Interplay between the maillard reaction and lipid peroxidation in biochemical systems. Ann N Y Acad Sci 1043, 319–326.
468Esterbauer H, Schaur RJ & Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11, 81–128.
469Uchida K (2000) Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med 28, 1685–1696.
470Fu MX, Requena JR, Jenkins AJ, et al. (1996) The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271, 9982–9986.
471Brownlee M (1995) Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46, 223–234.
472Basta G, Lazzerini G, Del TS, et al. (2005) At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol 25, 1401–1407.
473Jay D, Hitomi H & Griendling KK (2006) Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med 40, 183–192.
474Bierhaus A, Humpert PM, Morcos M, et al. (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83, 876–886.
475Bierhaus A, Rudofsky GJ & Humpert PM (2005) The immune response to food and its impact on atherogenesis. Diabetes Stoffwechsel Suppl. 1, 14–15.
476Lander HM, Tauras JM, Ogiste JS, et al. (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272, 17810–17814.
477Ramasamy R, Yan SF & Schmidt AM (2007) Arguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts. Mol Nutr Food Res 51, 1111–1115.
478Stern D, Yan SD, Yan SF, et al. (2002) Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 54, 1615–1625.
479Li YM, Mitsuhashi T, Wojciechowicz D, et al. (1996) Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci U S A 93, 11047–11052.
480Vlassara H, Li YM, Imani F, et al. (1995) Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1, 634–646.
481Heizmann CW (2007) The mechanism by which dietary AGEs are a risk to human health is via their interaction with RAGE: arguing against the motion. Mol Nutr Food Res 51, 1116–1119.
482Cai W, He JC, Zhu L, et al. (2006) Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci U S A 103, 13801–13806.
483Iacobini C, Amadio L, Oddi G, et al. (2003) Role of galectin-3 in diabetic nephropathy. J Am Soc Nephrol 14, S264–S270.
484Horiuchi S, Sakamoto Y & Sakai M (2003) Scavenger receptors for oxidized and glycated proteins. Amino Acids 25, 283–292.
485Greaves DR & Gordon S (2005) Thematic review series: the immune system and atherogenesis. Recent insights into the biology of macrophage scavenger receptors. J Lipid Res 46, 11–20.
486Murphy JE, Tedbury PR, Homer-Vanniasinkam S, et al. (2005) Biochemistry and cell biology of mammalian scavenger receptors. Atherosclerosis 182, 1–15.
487Moore KJ & Freeman MW (2006) Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol 26, 1702–1711.
488Nagai R, Mera K, Nakajou K, et al. (2007) The ligand activity of AGE-proteins to scavenger receptors is dependent on their rate of modification by AGEs. Biochim Biophys Acta 1772, 1192–1198.
489Park L, Raman KG, Lee KJ, et al. (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4, 1025–1031.
490Bucciarelli LG, Wendt T, Qu W, et al. (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106, 2827–2835.
491Flyvbjerg A, Denner L, Schrijvers BF, et al. (2004) Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53, 166–172.
492Yamamoto Y, Kato I, Doi T, et al. (2001) Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108, 261–268.
493Wendt TM, Tanji N, Guo J, et al. (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162, 1123–1137.
494Bierhaus A, Haslbeck KM, Humpert PM, et al. (2004) Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 114, 1741–1751.
495Haslbeck KM, Schleicher E, Bierhaus A, et al. (2005) The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes 113, 288–291.
496Pugliese G, Pricci F, Iacobini C, et al. (2001) Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J 15, 2471–2479.
497Iacobini C, Menini S, Oddi G, et al. (2004) Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J 18, 1773–1775.
498Iacobini C, Oddi G, Menini S, et al. (2005) Development of age-dependent glomerular lesions in galectin-3/AGE-receptor-3 knockout mice. Am J Physiol Renal Physiol 289, F611–F621.
499Arar C, Gaudin JC, Capron L, et al. (1998) Galectin-3 gene (LGALS3) expression in experimental atherosclerosis and cultured smooth muscle cells. FEBS Lett 430, 307–311.
500Nachtigal M, Al-Assaad Z, Mayer EP, et al. (1998) Galectin-3 expression in human atherosclerotic lesions. Am J Pathol 152, 1199–1208.
501Iacobini C, Menini S, Ricci C, et al. (2009) Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. Arterioscler Thromb Vasc Biol 29, 831–836.
502Lu C, He JC, Cai W, et al. (2004) Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci U S A 101, 11767–11772.
503He CJ, Zheng F, Stitt A, et al. (2000) Differential expression of renal AGE-receptor genes in NOD mice: possible role in nonobese diabetic renal disease. Kidney Int 58, 1931–1940.
504He CJ, Koschinsky T, Buenting C, et al. (2001) Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. Mol Med 7, 159–168.
505Finot PA, Bujard E, Mottu F, et al. (1977) Availability of the true Schiff's bases of lysine. Chemical evaluation of the Schiff's base between lysine and lactose in milk. Adv Exp Med Biol 86B, 343–365.
506Vlassara H & Palace MR (2003) Glycoxidation: the menace of diabetes and aging. Mt Sinai J Med 70, 232–241.
507Hofmann SM, Dong HJ, Li Z, et al. (2002) Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 51, 2082–2089.
508Sandu O, Song K, Cai W, et al. (2005) Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 54, 2314–2319.
509Peppa M, He C, Hattori M, et al. (2003) Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes 52, 1441–1448.
510Zheng F, He C, Cai W, et al. (2002) Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 18, 224–237.
511Lin RY, Choudhury RP, Cai W, et al. (2003) Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 168, 213–220.
512Lin RY, Reis ED, Dore AT, et al. (2002) Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis 163, 303–311.
513Peppa M, Brem H, Ehrlich P, et al. (2003) Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes 52, 2805–2813.
514Negrean M, Stirban A, Stratmann B, et al. (2007) Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 85, 1236–1243.
515Peppa M, Uribarri J, Cai W, et al. (2004) Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis 43, 690–695.
516Schiekofer S, Franke S, Andrassy M, et al. (2006) Postprandial mononuclear NF-kappaB activation is independent of the AGE-content of a single meal. Exp Clin Endocrinol Diabetes 114, 160–167.
517Sebekova K, Somoza V, Jarcuskova M, et al. (2009) Plasma advanced glycation end products are decreased in obese children compared with lean controls. Int J Pediatr Obes 4, 112–118.
518Stirban A, Negrean M, Stratmann B, et al. (2006) Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 29, 2064–2071.
519Uribarri J, Stirban A, Sander D, et al. (2007) Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 30, 2579–2582.
520Uribarri J, Cai W, Peppa M, et al. (2007) Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 62, 427–433.
521Vlassara H, Cai W, Crandall J, et al. (2002) Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 99, 15596–15601.
522Venkatesan A, Hemalatha A, Bobby Z, et al. (2006) Nonenzymatic glycation of plasma proteins in smokers. Indian J Physiol Pharmacol 50, 403–408.
523Uribarri J, Peppa M, Cai W, et al. (2003) Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 14, 728–731.
524Busch M, Franke S, Wolf G, et al. (2006) The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. Am J Kidney Dis 48, 571–579.
525Schwedler SB, Metzger T, Schinzel R, et al. (2002) Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 62, 301–310.
526Baynes JW (2007) Dietary ALEs are a risk to human health–NOT!. Mol Nutr Food Res 51, 1102–1106.
527Tessier FJ & Birlouez-Aragon I (2010) Health effects of dietary Maillard reaction products: the results of ICARE and other studies. Amino Acids .
528Faist V & Erbersdobler HF (2001) Metabolic transit and in vivo effects of melanoidins and precursor compounds deriving from the Maillard reaction. Ann Nutr Metab 45, 1–12.
529Somoza V, Wenzel E, Weiss C, et al. (2006) Dose-dependent utilisation of casein-linked lysinoalanine, N(epsilon)-fructoselysine and N(epsilon)-carboxymethyllysine in rats. Mol Nutr Food Res 50, 833–841.
530Hultsch C, Hellwig M, Pawelke B, et al. (2006) Biodistribution and catabolism of 18F-labeled N-epsilon-fructoselysine as a model of Amadori products. Nucl Med Biol 33, 865–873.
531Somoza V (2005) Five years of research on health risks and benefits of Maillard reaction products: an update. Mol Nutr Food Res 49, 663–672.
532Foerster A & Henle T (2003) Glycation in food and metabolic transit of dietary AGEs (advanced glycation end-products): studies on the urinary excretion of pyrraline. Biochem Soc Trans 31, 1383–1385.
533Miyata T, Ueda Y, Horie K, et al. (1998) Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 53, 416–422.
534Wiame E, Delpierre G, Collard F, et al. (2002) Identification of a pathway for the utilization of the Amadori product fructoselysine in Escherichia coli. J Biol Chem 277, 42523–42529.
535Penfold SA, Coughlan MT, Patel SK, et al. (2010) Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int 78, 287–295.
536Hammes HP, Du X, Edelstein D, et al. (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9, 294–299.
537Mehta R, Shangari N & O'Brien PJ (2008) Preventing cell death induced by carbonyl stress, oxidative stress or mitochondrial toxins with vitamin B anti-AGE agents. Mol Nutr Food Res 52, 379–385.
538Thornalley PJ, Babaei-Jadidi R, Al AH, et al. (2007) High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 50, 2164–2170.
539Ostendorp T, Leclerc E, Galichet A, et al. (2007) Structural and functional insights into RAGE activation by multimeric S100B. EMBO J 26, 3868–3878.
540Schleicher ED (2010) A race for RAGE ligands. Kidney Int 78, 234–236.
541Xie J, Reverdatto S, Frolov A, et al. (2008) Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem 283, 27255–27269.
542Buetler TM, Latado H, Leclerc E, et al. (2011) Glycolaldehyde-modified beta-lactoglobulin AGEs are unable to stimulate inflammatory signaling pathways in RAGE-expressing human cell lines. Mol Nutr Food Res 55, 291–299.
543Reznikov LL, Waksman J, Azam T, et al. (2004) Effect of advanced glycation end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells. Clin Nephrol 61, 324–336.
544Ahmed N, Mirshekar-Syahkal B, Kennish L, et al. (2005) Assay of advanced glycation endproducts in selected beverages and food by liquid chromatography with tandem mass spectrometric detection. Mol Nutr Food Res 49, 691–699.
545Uribarri J, Woodruff S, Goodman S, et al. (2010) Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 110, 911–916.
546Assar SH, Moloney C, Lima M, et al. (2009) Determination of Nepsilon-(carboxymethyl)lysine in food systems by ultra performance liquid chromatography–mass spectrometry. Amino Acids 36, 317–326.
547Morales FJ, Somoza V & Fogliano V (2010) Physiological relevance of dietary melanoidins. Amino Acids .
548Chuyen NV, Arai H, Nakanishi T, et al. (2005) Are food advanced glycation end products toxic in biological systems? Ann N Y Acad Sci 1043, 467–473.
549Rudofsky G Jr, Reismann P, Schiekofer S, et al. (2004) Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs. Horm Metab Res 36, 630–638.
550Monnier L, Mas E, Ginet C, et al. (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295, 1681–1687.
551Ceriello A (2005) Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54, 1–7.
552Giacco F & Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107, 1058–1070.
553Schindhelm RK, Alssema M, Scheffer PG, et al. (2007) Fasting and postprandial glycoxidative and lipoxidative stress are increased in women with type 2 diabetes. Diabetes Care 30, 1789–1794.
554Alipour A, Elte JW, van Zaanen HC, et al. (2007) Postprandial inflammation and endothelial dysfuction. Biochem Soc Trans 35, 466–469.
555Sourris KC, Forbes JM & Cooper ME (2008) Therapeutic interruption of advanced glycation in diabetic nephropathy: do all roads lead to Rome? Ann N Y Acad Sci 1126, 101–106.
556Spiteller G (2008) Peroxyl radicals are essential reagents in the oxidation steps of the Maillard reaction leading to generation of advanced glycation end products. Ann N Y Acad Sci 1126, 128–133.
557He C, Sabol J, Mitsuhashi T, et al. (1999) Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 48, 1308–1315.
558Shangari N, Depeint F, Furrer R, et al. (2005) The effects of partial thiamin deficiency and oxidative stress (i.e. glyoxal and methylglyoxal) on the levels of alpha-oxoaldehyde plasma protein adducts in Fischer 344 rats. FEBS Lett 579, 5596–5602.
559Shangari N, Depeint F, Furrer R, et al. (2007) A thermolyzed diet increases oxidative stress, plasma alpha-aldehydes and colonic inflammation in the rat. Chem Biol Interact 169, 100–109.
560Sebekova K, Krajcoviova-Kudlackova M, Schinzel R, et al. (2001) Plasma levels of advanced glycation end products in healthy, long-term vegetarians and subjects on a western mixed diet. Eur J Nutr 40, 275–281.
561Schalkwijk CG (2006) Is reduction of AGEs in food a potential medical nutrition therapy: are AGEs the real culprits? IMARS Highlights 1, 8.
562Tai AW & Newkirk MM (2000) An autoantibody targeting glycated IgG is associated with elevated serum immune complexes in rheumatoid arthritis (RA). Clin Exp Immunol 120, 188–193.
563Turk Z, Ljubic S, Turk N, et al. (2001) Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus. Clin Chim Acta 303, 105–115.
564Ames JM, Wynne A, Hofmann A, et al. (1999) The effect of a model melanoidin mixture on faecal bacterial populations in vitro. Br J Nutr 82, 489–495.
565Dittrich R, Dragonas C, Kannenkeril D, et al. (2009) A diet rich in Maillard reaction products protects LDL against copper induced oxidation ex vivo, a human intervention trial. Food Res Int 42, 1315–1322.
566Lindenmeier M, Faist V & Hofmann T (2002) Structural and functional characterization of pronyl-lysine, a novel protein modification in bread crust melanoidins showing in vitro antioxidative and phase I/II enzyme modulating activity. J Agric Food Chem 50, 6997–7006.
567Marko D, Habermeyer M, Kemeny M, et al. (2003) Maillard reaction products modulating the growth of human tumor cells in vitro. Chem Res Toxicol 16, 48–55.
568Chuyen NV (2006) Toxicity of the AGEs generated from the Maillard reaction: on the relationship of food-AGEs and biological-AGEs. Mol Nutr Food Res 50, 1140–1149.
569Calder PC (2003) n-3 Polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 38, 343–352.
570Calder PC (2006) n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83, 1505S–1519S.
571van den Berghe W, Vermeulen L, Delerive P, et al. (2003) A paradigm for gene regulation: inflammation, NF-kappaB and PPAR. Adv Exp Med Biol 544, 181–196.
572Weigert C, Brodbeck K, Staiger H, et al. (2004) Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteasome-dependent activation of nuclear factor-kappaB. J Biol Chem 279, 23942–23952.
573Ajuwon KM & Spurlock ME (2005) Palmitate activates the NF-kappaB transcription factor and induces IL-6 and TNFalpha expression in 3T3-L1 adipocytes. J Nutr 135, 1841–1846.
574Lee JY, Plakidas A, Lee WH, et al. (2003) Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 Polyunsaturated fatty acids. J Lipid Res 44, 479–486.
575Weatherill AR, Lee JY, Zhao L, et al. (2005) Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4. J Immunol 174, 5390–5397.
576Eschen O, Christensen JH, Toft E, et al. (2005) Soluble adhesion molecules and marine n-3 fatty acids in patients referred for coronary angiography. Atherosclerosis 180, 327–331.
577Fernandez-Real JM, Broch M, Vendrell J, et al. (2003) Insulin resistance, inflammation, and serum fatty acid composition. Diabetes Care 26, 1362–1368.
578Ferrucci L, Cherubini A, Bandinelli S, et al. (2006) Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 91, 439–446.
579Klein-Platat C, Drai J, Oujaa M, et al. (2005) Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. Am J Clin Nutr 82, 1178–1184.
580Lopez-Garcia E, Schulze MB, Meigs JB, et al. (2005) Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J Nutr 135, 562–566.
581Niu K, Hozawa A, Kuriyama S, et al. (2006) Dietary long-chain n-3 fatty acids of marine origin and serum C-reactive protein concentrations are associated in a population with a diet rich in marine products. Am J Clin Nutr 84, 223–229.
582Petersson H, Basu S, Cederholm T, et al. (2008) Serum fatty acid composition and indices of stearoyl-CoA desaturase activity are associated with systemic inflammation: longitudinal analyses in middle-aged men. Br J Nutr 99, 1186–1189.
583Pischon T, Hankinson SE, Hotamisligil GS, et al. (2003) Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation 108, 155–160.
584Poudel-Tandukar K, Nanri A, Matsushita Y, et al. (2009) Dietary intakes of alpha-linolenic and linoleic acids are inversely associated with serum C-reactive protein levels among Japanese men. Nutr Res 29, 363–370.
585Yli-Jama P, Seljeflot I, Meyer HE, et al. (2002) Serum non-esterified very long-chain PUFA are associated with markers of endothelial dysfunction. Atherosclerosis 164, 275–281.
586Baer DJ, Judd JT, Clevidence BA, et al. (2004) Dietary fatty acids affect plasma markers of inflammation in healthy men fed controlled diets: a randomized crossover study. Am J Clin Nutr 79, 969–973.
587Li G, Barnes D, Butz D, et al. (2005) 10t,12c-conjugated linoleic acid inhibits lipopolysaccharide-induced cyclooxygenase expression in vitro and in vivo. J Lipid Res 46, 2134–2142.
588Li G, Dong B, Butz DE, et al. (2006) NF-kappaB independent inhibition of lipopolysaccharide-induced cyclooxygenase by a conjugated linoleic acid cognate, conjugated nonadecadienoic acid. Biochim Biophys Acta 1761, 969–972.
589Moloney F, Toomey S, Noone E, et al. (2007) Antidiabetic effects of cis-9, trans-11-conjugated linoleic acid may be mediated via anti-inflammatory effects in white adipose tissue. Diabetes 56, 574–582.
590Mullen A, Moloney F, Nugent AP, et al. (2007) Conjugated linoleic acid supplementation reduces peripheral blood mononuclear cell interleukin-2 production in healthy middle-aged males. J Nutr Biochem 18, 658–666.
591Nugent AP, Roche HM, Noone EJ, et al. (2005) The effects of conjugated linoleic acid supplementation on immune function in healthy volunteers. Eur J Clin Nutr 59, 742–750.
592Ramakers JD, Plat J, Sebedio JL, et al. (2005) Effects of the individual isomers cis-9, trans-11 vs. trans-10, cis-12 of conjugated linoleic acid (CLA) on inflammation parameters in moderately overweight subjects with LDL-phenotype B. Lipids 40, 909–918.
593Riserus U, Basu S, Jovinge S, et al. (2002) Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated C-reactive protein: a potential link to fatty acid-induced insulin resistance. Circulation 106, 1925–1929.
594Smedman A, Basu S, Jovinge S, et al. (2005) Conjugated linoleic acid increased C-reactive protein in human subjects. Br J Nutr 94, 791–795.
595Song HJ, Grant I, Rotondo D, et al. (2005) Effect of CLA supplementation on immune function in young healthy volunteers. Eur J Clin Nutr 59, 508–517.
596Tricon S, Burdge GC, Kew S, et al. (2004) Effects of cis-9, trans-11 and trans-10, cis-12 conjugated linoleic acid on immune cell function in healthy humans. Am J Clin Nutr 80, 1626–1633.
597Turpeinen AM, Basu S & Mutanen M (1998) A high linoleic acid diet increases oxidative stress in vivo and affects nitric oxide metabolism in humans. Prostaglandins Leukot Essent Fatty Acids 59, 229–233.
598Burdge GC & Calder PC (2006) Dietary alpha-linolenic acid and health-related outcomes: a metabolic perspective. Nutr Res Rev 19, 26–52.
599Bemelmans WJ, Lefrandt JD, Feskens EJ, et al. (2004) Increased alpha-linolenic acid intake lowers C-reactive protein, but has no effect on markers of atherosclerosis. Eur J Clin Nutr 58, 1083–1089.
600Junker R, Pieke B, Schulte H, et al. (2001) Changes in hemostasis during treatment of hypertriglyceridemia with a diet rich in monounsaturated and n-3 polyunsaturated fatty acids in comparison with a low-fat diet. Thromb Res 101, 355–366.
601Paschos GK, Rallidis LS, Liakos GK, et al. (2004) Background diet influences the anti-inflammatory effect of alpha-linolenic acid in dyslipidaemic subjects. Br J Nutr 92, 649–655.
602Paschos GK, Zampelas A, Panagiotakos DB, et al. (2007) Effects of flaxseed oil supplementation on plasma adiponectin levels in dyslipidemic men. Eur J Nutr 46, 315–320.
603Rallidis LS, Paschos G, Liakos GK, et al. (2003) Dietary alpha-linolenic acid decreases C-reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients. Atherosclerosis 167, 237–242.
604Rallidis LS, Paschos G, Papaioannou ML, et al. (2004) The effect of diet enriched with alpha-linolenic acid on soluble cellular adhesion molecules in dyslipidaemic patients. Atherosclerosis 174, 127–132.
605Thies F, Miles EA, Nebe-von-Caron G, et al. (2001) Influence of dietary supplementation with long-chain n-3 or n-6 polyunsaturated fatty acids on blood inflammatory cell populations and functions and on plasma soluble adhesion molecules in healthy adults. Lipids 36, 1183–1193.
606Zhao G, Etherton TD, Martin KR, et al. (2004) Dietary alpha-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. J Nutr 134, 2991–2997.
607Liou YA, King DJ, Zibrik D, et al. (2007) Decreasing linoleic acid with constant alpha-linolenic acid in dietary fats increases (n-3) eicosapentaenoic acid in plasma phospholipids in healthy men. J Nutr 137, 945–952.
608Calder PC (2009) Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 91, 791–795.
609Kelley DS, Taylor PC, Nelson GJ, et al. (1997) Effects of dietary arachidonic acid on human immune response. Lipids 32, 449–456.
610Yaqoob P, Pala HS, Cortina-Borja M, et al. (2000) Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions. Eur J Clin Invest 30, 260–274.
611Healy DA, Wallace FA, Miles EA, et al. (2000) Effect of low-to-moderate amounts of dietary fish oil on neutrophil lipid composition and function. Lipids 35, 763–768.
612Rees D, Miles EA, Banerjee T, et al. (2006) Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am J Clin Nutr 83, 331–342.
613Calder PC (2007) Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 77, 327–335.
614Calder PC (2008) The relationship between the fatty acid composition of immune cells and their function. Prostaglandins Leukot Essent Fatty Acids 79, 101–108.
615Calder PC (2008) PUFA, inflammatory processes and rheumatoid arthritis. Proc Nutr Soc 67, 409–418.
616Calder PC (2008) Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 52, 885–897.
617Kremmyda LS, Vlachava M, Noakes PS, et al. (2009) Atopy risk in infants and children in relation to early exposure to fish, oily fish, or long-chain omega-3 fatty acids: a systematic review. Clin Rev Allergy Immunol 41, 36–66.
618Abe Y, El-Masri B, Kimball KT, et al. (1998) Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol 18, 723–731.
619Berstad P, Seljeflot I, Veierod MB, et al. (2003) Supplementation with fish oil affects the association between very long-chain n-3 Polyunsaturated fatty acids in serum non-esterified fatty acids and soluble vascular cell adhesion molecule-1. Clin Sci (Lond) 105, 13–20.
620Blok WL, Deslypere JP, Demacker PN, et al. (1997) Pro- and anti-inflammatory cytokines in healthy volunteers fed various doses of fish oil for 1 year. Eur J Clin Invest 27, 1003–1008.
621Browning LM, Krebs JD, Moore CS, et al. (2007) The impact of long chain n-3 Polyunsaturated fatty acid supplementation on inflammation, insulin sensitivity and CVD risk in a group of overweight women with an inflammatory phenotype. Diabetes Obes Metab 9, 70–80.
622Cazzola R, Russo-Volpe S, Miles EA, et al. (2007) Age- and dose-dependent effects of an eicosapentaenoic acid-rich oil on cardiovascular risk factors in healthy male subjects. Atherosclerosis 193, 159–167.
623Chan DC, Watts GF, Mori TA, et al. (2002) Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest 32, 429–436.
624Ciubotaru I, Lee YS & Wander RC (2003) Dietary fish oil decreases C-reactive protein, interleukin-6, and triacylglycerol to HDL-cholesterol ratio in postmenopausal women on HRT. J Nutr Biochem 14, 513–521.
625Eschen O, Christensen JH, De CR, et al. (2004) Soluble adhesion molecules in healthy subjects: a dose–response study using n-3 fatty acids. Nutr Metab Cardiovasc Dis 14, 180–185.
626Fujioka S, Hamazaki K, Itomura M, et al. (2006) The effects of eicosapentaenoic acid-fortified food on inflammatory markers in healthy subjects – a randomized, placebo-controlled, double-blind study. J Nutr Sci Vitaminol (Tokyo) 52, 261–265.
627Grundt H, Nilsen DW, Mansoor MA, et al. (2003) Reduction in homocysteine by n-3 Polyunsaturated fatty acids after 1 year in a randomised double-blind study following an acute myocardial infarction: no effect on endothelial adhesion properties. Pathophysiol Haemost Thromb 33, 88–95.
628Hjerkinn EM, Seljeflot I, Ellingsen I, et al. (2005) Influence of long-term intervention with dietary counseling, long-chain n-3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long-standing hyperlipidemia. Am J Clin Nutr 81, 583–589.
629Johansen O, Seljeflot I, Hostmark AT, et al. (1999) The effect of supplementation with omega-3 fatty acids on soluble markers of endothelial function in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 19, 1681–1686.
630Kabir M, Skurnik G, Naour N, et al. (2007) Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am J Clin Nutr 86, 1670–1679.
631Kelley DS, Siegel D, Fedor DM, et al. (2009) DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men. J Nutr 139, 495–501.
632Krebs JD, Browning LM, McLean NK, et al. (2006) Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women. Int J Obes (Lond) 30, 1535–1544.
633Madsen T, Christensen JH, Blom M, et al. (2003) The effect of dietary n-3 fatty acids on serum concentrations of C-reactive protein: a dose–response study. Br J Nutr 89, 517–522.
634Madsen T, Schmidt EB & Christensen JH (2007) The effect of n-3 fatty acids on C-reactive protein levels in patients with chronic renal failure. J Ren Nutr 17, 258–263.
635Madsen T, Christensen JH & Schmidt EB (2007) C-reactive protein and n-3 fatty acids in patients with a previous myocardial infarction: a placebo-controlled randomized study. Eur J Nutr 46, 428–430.
636Mori TA, Woodman RJ, Burke V, et al. (2003) Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 35, 772–781.
637Murphy KJ, Meyer BJ, Mori TA, et al. (2007) Impact of foods enriched with n-3 long-chain polyunsaturated fatty acids on erythrocyte n-3 levels and cardiovascular risk factors. Br J Nutr 97, 749–757.
638Pot GK, Brouwer IA, Enneman A, et al. (2009) No effect of fish oil supplementation on serum inflammatory markers and their interrelationships: a randomized controlled trial in healthy, middle-aged individuals. Eur J Clin Nutr 63, 1353–1359.
639Rasic-Milutinovic Z, Perunicic G, Pljesa S, et al. (2007) Effects of N-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients. Ren Fail 29, 321–329.
640Sampson MJ, Davies IR, Brown JC, et al. (2001) n-3 polyunsaturated fatty acid supplementation, monocyte adhesion molecule expression and pro-inflammatory mediators in type 2 diabetes mellitus. Diabet Med 18, 51–58.
641Sanders TA, Lewis F, Slaughter S, et al. (2006) Effect of varying the ratio of n-6 to n-3 fatty acids by increasing the dietary intake of alpha-linolenic acid, eicosapentaenoic and docosahexaenoic acid, or both on fibrinogen and clotting factors VII and XII in persons aged 45–70 y: the OPTILIP study. Am J Clin Nutr 84, 513–522.
642Seljeflot I, Arnesen H, Brude IR, et al. (1998) Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers. Eur J Clin Invest 28, 629–635.
643Troseid M, Arnesen H, Hjerkinn EM, et al. (2009) Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men. Metabolism 58, 1543–1549.
644Woodman RJ, Mori TA, Burke V, et al. (2003) Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis 166, 85–93.
645Yamada H, Yoshida M, Nakano Y, et al. (2008) In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid. Arterioscler Thromb Vasc Biol 28, 2173–2179.
646Yusof HM, Miles EA & Calder PC (2008) Influence of very long-chain n-3 fatty acids on plasma markers of inflammation in middle-aged men. Prostaglandins Leukot Essent Fatty Acids 78, 219–228.
647Todoric J, Loffler M, Huber J, et al. (2006) Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 49, 2109–2119.
648Rossi AS, Lombardo YB, Lacorte JM, et al. (2005) Dietary fish oil positively regulates plasma leptin and adiponectin levels in sucrose-fed, insulin-resistant rats. Am J Physiol Regul Integr Comp Physiol 289, R486–R494.
649Grimble RF, Howell WM, O'Reilly G, et al. (2002) The ability of fish oil to suppress tumor necrosis factor alpha production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor alpha production. Am J Clin Nutr 76, 454–459.
650Shen J, Arnett DK, Peacock JM, et al. (2007) Interleukin1beta genetic polymorphisms interact with polyunsaturated fatty acids to modulate risk of the metabolic syndrome. J Nutr 137, 1846–1851.
651Ceriello A, Quagliaro L, Piconi L, et al. (2004) Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 53, 701–710.
652Ceriello A, Taboga C, Tonutti L, et al. (2002) Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 106, 1211–1218.
653Kempf K, Rose B, Herder C, et al. (2007) The metabolic syndrome sensitizes leukocytes for glucose-induced immune gene expression. J Mol Med 85, 389–396.
654Giugliano D, Ceriello A & Esposito K (2006) The effects of diet on inflammation: emphasis on the metabolic syndrome. J Am Coll Cardiol 48, 677–685.
655Davidson SM & Duchen MR (2007) Endothelial mitochondria: contributing to vascular function and disease. Circ Res 100, 1128–1141.
656Mohan IK & Das UN (1998) Effect of l-arginine-nitric oxide system on chemical-induced diabetes mellitus. Free Radic Biol Med 25, 757–765.
657Williams SB, Goldfine AB, Timimi FK, et al. (1998) Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97, 1695–1701.
658Scognamiglio R, Negut C, De Kreutzenberg SV, et al. (2005) Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 112, 179–184.
659Jacob S, Ruus P, Hermann R, et al. (1999) Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med 27, 309–314.
660Caballero B (1993) Vitamin E improves the action of insulin. Nutr Rev 51, 339–340.
661May JM (2000) How does ascorbic acid prevent endothelial dysfunction? Free Radic Biol Med 28, 1421–1429.
662Evans JL, Goldfine ID, Maddux BA, et al. (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23, 599–622.
663Giugliano D, Marfella R, Coppola L, et al. (1997) Vascular effects of acute hyperglycemia in humans are reversed by l-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 95, 1783–1790.
664Ceriello A, Bortolotti N, Motz E, et al. (1999) Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism 48, 1503–1508.
665Ursini F, Zamburlini A, Cazzolato G, et al. (1998) Postprandial plasma lipid hydroperoxides: a possible link between diet and atherosclerosis. Free Radic Biol Med 25, 250–252.
666Marfella R, Quagliaro L, Nappo F, et al. (2001) Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 108, 635–636.
667Price KD, Price CS & Reynolds RD (2001) Hyperglycemia-induced ascorbic acid deficiency promotes endothelial dysfunction and the development of atherosclerosis. Atherosclerosis 158, 1–12.
668Chen MS, Hutchinson ML, Pecoraro RE, et al. (1983) Hyperglycemia-induced intracellular depletion of ascorbic acid in human mononuclear leukocytes. Diabetes 32, 1078–1081.
669Beisswenger PJ, Howell SK, O'Dell RM, et al. (2001) alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 24, 726–732.
670Cai W, He JC, Zhu L, et al. (2004) High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 110, 285–291.
671Kempf K, Rose B, Herder C, et al. (2006) Inflammation in metabolic syndrome and type 2 diabetes: impact of dietary glucose. Ann N Y Acad Sci 1084, 30–48.
672Levitan EB, Cook NR, Stampfer MJ, et al. (2008) Dietary glycemic index, dietary glycemic load, blood lipids, and C-reactive protein. Metabolism 57, 437–443.
673Du H, van der AD, van Bakel MM, et al. (2008) Glycemic index and glycemic load in relation to food and nutrient intake and metabolic risk factors in a Dutch population. Am J Clin Nutr 87, 655–661.
674Pittas AG, Roberts SB, Das SK, et al. (2006) The effects of the dietary glycemic load on type 2 diabetes risk factors during weight loss. Obesity (Silver Spring) 14, 2200–2209.
675Shikany JM, Phadke RP, Redden DT, et al. (2009) Effects of low- and high-glycemic index/glycemic load diets on coronary heart disease risk factors in overweight/obese men. Metabolism 58, 1793–1801.
676Vrolix R & Mensink RP (2010) Effects of glycemic load on metabolic risk markers in subjects at increased risk of developing metabolic syndrome. Am J Clin Nutr 92, 366–374.
677Ajani UA, Ford ES & Mokdad AH (2004) Dietary fiber and C-reactive protein: findings from national health and nutrition examination survey data. J Nutr 134, 1181–1185.
678King DE, Mainous AG III, Egan BM, et al. (2005) Fiber and C-reactive protein in diabetes, hypertension, and obesity. Diabetes Care 28, 1487–1489.
679Bo S, Durazzo M, Guidi S, et al. (2006) Dietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohort. Am J Clin Nutr 84, 1062–1069.
680Ma Y, Griffith JA, Chasan-Taber L, et al. (2006) Association between dietary fiber and serum C-reactive protein. Am J Clin Nutr 83, 760–766.
681Ma Y, Hebert JR, Li W, et al. (2008) Association between dietary fiber and markers of systemic inflammation in the Women's Health Initiative Observational Study. Nutrition 24, 941–949.
682King DE, Egan BM, Woolson RF, et al. (2007) Effect of a high-fiber diet vs a fiber-supplemented diet on C-reactive protein level. Arch Intern Med 167, 502–506.
683Zemel MB & Sun X (2008) Dietary calcium and dairy products modulate oxidative and inflammatory stress in mice and humans. J Nutr 138, 1047–1052.
684Jauhiainen T, Vapaatalo H, Poussa T, et al. (2005) Lactobacillus helveticus fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement. Am J Hypertens 18, 1600–1605.
685Pins JJ & Keenan JM (2006) Effects of whey peptides on cardiovascular disease risk factors. J Clin Hypertens (Greenwich) 8, 775–782.
686Lee YM, Skurk T, Hennig M, et al. (2007) Effect of a milk drink supplemented with whey peptides on blood pressure in patients with mild hypertension. Eur J Nutr 46, 21–27.
687Crouch SP, Slater KJ & Fletcher J (1992) Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood 80, 235–240.
688Conneely OM (2001) Antiinflammatory activities of lactoferrin. J Am Coll Nutr 20, 389S–395S.
689Legrand D, Elass E, Carpentier M, et al. (2005) Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci 62, 2549–2559.
690Ahluwalia N (1998) Diagnostic utility of serum transferrin receptors measurement in assessing iron status. Nutr Rev 56, 133–141.
691Weiss G & Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352, 1011–1023.
692Baynes RD (1996) Assessment of iron status. Clin Biochem 29, 209–215.
693Cook JD, Flowers CH & Skikne BS (2003) The quantitative assessment of body iron. Blood 101, 3359–3364.
694Northrop-Clewes CA (2008) Interpreting indicators of iron status during an acute phase response–lessons from malaria and human immunodeficiency virus. Ann Clin Biochem 45, 18–32.
695Weiss G (2002) Iron and immunity: a double-edged sword. Eur J Clin Invest 32, Suppl. 1, 70–78.
696Ahluwalia N, Sun J, Krause D, et al. (2004) Immune function is impaired in iron-deficient, homebound, older women. Am J Clin Nutr 79, 516–521.
697de Silva A, Atukorala S, Weerasinghe I, et al. (2003) Iron supplementation improves iron status and reduces morbidity in children with or without upper respiratory tract infections: a randomized controlled study in Colombo, Sri Lanka. Am J Clin Nutr 77, 234–241.
698Wood RJ (2004) The iron-heart disease connection: is it dead or just hiding? Ageing Res Rev 3, 355–367.
699Wagener FA, Volk HD, Willis D, et al. (2003) Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev 55, 551–571.
700McCord JM (1998) Iron, free radicals, and oxidative injury. Semin Hematol 35, 5–12.
701Lee DH & Jacobs DR Jr (2004) Serum markers of stored body iron are not appropriate markers of health effects of iron: a focus on serum ferritin. Med Hypotheses 62, 442–445.
702Rajpathak S, Ma J, Manson J, et al. (2006) Iron intake and the risk of type 2 diabetes in women: a prospective cohort study. Diabetes Care 29, 1370–1376.
703Ascherio A, Willett WC, Rimm EB, et al. (1994) Dietary iron intake and risk of coronary disease among men. Circulation 89, 969–974.
704Jiang R, Ma J, Ascherio A, et al. (2004) Dietary iron intake and blood donations in relation to risk of type 2 diabetes in men: a prospective cohort study. Am J Clin Nutr 79, 70–75.
705Wrede CE, Buettner R, Bollheimer LC, et al. (2006) Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur J Endocrinol 154, 333–340.
706Fernandez-Real JM, Moreno JM, Lopez-Bermejo A, et al. (2007) Circulating soluble transferrin receptor according to glucose tolerance status and insulin sensitivity. Diabetes Care 30, 604–608.
707Jehn M, Clark JM & Guallar E (2004) Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 27, 2422–2428.
708Alissa EM, Ahmed WH, Al-Ama N, et al. (2007) Relationship between indices of iron status and coronary risk factors including diabetes and the metabolic syndrome in Saudi subjects without overt coronary disease. J Trace Elem Med Biol 21, 242–254.
709Sullivan JL (1989) The iron paradigm of ischemic heart disease. Am Heart J 117, 1177–1188.
710Salonen JT, Nyyssonen K, Korpela H, et al. (1992) High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 86, 803–811.
711Kiechl S, Willeit J, Egger G, et al. (1997) Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 96, 3300–3307.
712Ramakrishnan U, Kuklina E & Stein AD (2002) Iron stores and cardiovascular disease risk factors in women of reproductive age in the United States. Am J Clin Nutr 76, 1256–1260.
713Danesh J & Appleby P (1999) Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation 99, 852–854.
714Ahluwalia N, Genoux A, Ferrieres J, et al. (2010) Iron status is associated with carotid atherosclerotic plaques in middle-aged adults. J Nutr 140, 812–816.
715Facchini FS & Saylor KL (2002) Effect of iron depletion on cardiovascular risk factors: studies in carbohydrate-intolerant patients. Ann N Y Acad Sci 967, 342–351.
716Selzer CC & Mayer J (1963) Serum iron and iron-binding capacity in adolescents. II. Comparison of obese and nonobese subects. Am J Clin Nutr 13, 354–361.
717Nead KG, Halterman JS, Kaczorowski JM, et al. (2004) Overweight children and adolescents: a risk group for iron deficiency. Pediatrics 114, 104–108.
718Micozzi MS, Albanes D & Stevens RG (1989) Relation of body size and composition to clinical biochemical and hematologic indices in US men and women. Am J Clin Nutr 50, 1276–1281.
719Gillum RF (2001) Association of serum ferritin and indices of body fat distribution and obesity in Mexican American men – the Third National Health and Nutrition Examination Survey. Int J Obes Relat Metab Disord 25, 639–645.
720Lecube A, Carrera A, Losada E, et al. (2006) Iron deficiency in obese postmenopausal women. Obesity (Silver Spring) 14, 1724–1730.
721Yanoff LB, Menzie CM, Denkinger B, et al. (2007) Inflammation and iron deficiency in the hypoferremia of obesity. Int J Obes (Lond) 31, 1412–1419.
722Anty R, Dahman M, Iannelli A, et al. (2008) Bariatric surgery can correct iron depletion in morbidly obese women: a link with chronic inflammation. Obes Surg 18, 709–714.
723Hodgson JM, Ward NC, Burke V, et al. (2007) Increased lean red meat intake does not elevate markers of oxidative stress and inflammation in humans. J Nutr 137, 363–367.
724Rosales FJ, Kang Y, Pfeiffer B, et al. (2004) Twice the recommended daily allowance of iron is associated with an increase in plasma [alpha]-1 antichymotrypsin concentrations in Guatemalan school-aged children. Nutr Res 24, 875–887.
725Schumann K, Kroll S, Weiss G, et al. (2005) Monitoring of hematological, inflammatory and oxidative reactions to acute oral iron exposure in human volunteers: preliminary screening for selection of potentially-responsive biomarkers. Toxicology 212, 10–23.
726Krafft A, Perewusnyk G, Hanseler E, et al. (2005) Effect of postpartum iron supplementation on red cell and iron parameters in non-anaemic iron-deficient women: a randomised placebo-controlled study. BJOG 112, 445–450.
727Froicu M, Zhu Y & Cantorna MT (2006) Vitamin D receptor is required to control gastrointestinal immunity in IL-10 knockout mice. Immunology 117, 310–318.
728Baeke F, van EE, Gysemans C, et al. (2008) Vitamin D signaling in immune-mediated disorders: evolving insights and therapeutic opportunities. Mol Aspects Med 29, 376–387.
729Sun X & Zemel MB (2007) Calcium and 1,25-dihydroxyvitamin D3 regulation of adipokine expression. Obesity (Silver Spring) 15, 340–348.
730Borradale D & Kimlin M (2009) Vitamin D in health and disease: an insight into traditional functions and new roles for the ‘sunshine vitamin’. Nutr Res Rev 22, 118–136.
731Talmor Y, Golan E, Benchetrit S, et al. (2008) Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol 294, F1059–F1064.
732Martinesi M, Treves C, d'Albasio G, et al. (2008) Vitamin D derivatives induce apoptosis and downregulate ICAM-1 levels in peripheral blood mononuclear cells of inflammatory bowel disease patients. Inflamm Bowel Dis 14, 597–604.
733Giulietti A, van EE, Overbergh L, et al. (2007) Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract 77, 47–57.
734Cohen-Lahav M, Douvdevani A, Chaimovitz C, et al. (2007) The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J Steroid Biochem Mol Biol 103, 558–562.
735Sadeghi K, Wessner B, Laggner U, et al. (2006) Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol 36, 361–370.
736Hewison M (2008) Vitamin D and innate immunity. Curr Opin Investig Drugs 9, 485–490.
737Do JE, Kwon SY, Park S, et al. (2008) Effects of vitamin D on expression of Toll-like receptors of monocytes from patients with Behcet's disease. Rheumatology (Oxford) 47, 840–848.
738Aparna R, Subhashini J, Roy KR, et al. (2008) Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog. J Cell Biochem 104, 1832–1842.
739Ziv E, Rotem C, Miodovnik M, et al. (2008) Two modes of ERK activation by TNF in keratinocytes: different cellular outcomes and bi-directional modulation by vitamin D. J Cell Biochem 104, 606–619.
740Richards JB, Valdes AM, Gardner JP, et al. (2007) Higher serum vitamin D concentrations are associated with longer leukocyte telomere length in women. Am J Clin Nutr 86, 1420–1425.
741Shea MK, Booth SL, Massaro JM, et al. (2008) Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am J Epidemiol 167, 313–320.
742Michos ED, Streeten EA, Ryan KA, et al. (2009) Serum 25-hydroxyvitamin D levels are not associated with subclinical vascular disease or C-reactive protein in the old order amish. Calcif Tissue Int 84, 195–202.
743Jorde R, Sneve M, Torjesen PA, et al. (2010) No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine 50, 175–180.
744Hypponen E, Berry D, Cortina-Borja M, et al. (2010) 25-Hydroxyvitamin D and pre-clinical alterations in inflammatory and hemostatic markers: a cross sectional analysis in the 1958 British Birth Cohort. PLoS One 5, e10801.
745Vilarrasa N, Vendrell J, Maravall J, et al. (2010) Is plasma 25(OH) D related to adipokines, inflammatory cytokines and insulin resistance in both a healthy and morbidly obese population? Endocrine 38, 235–242.
746Jablonski KL, Chonchol M, Pierce GL, et al. (2011) 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension 57, 63–69.
747Devaraj S, Yun JM, Duncan-Staley CR, et al. (2011) Low vitamin D levels correlate with the proinflammatory state in type 1 diabetic subjects with and without microvascular complications. Am J Clin Pathol 135, 429–433.
748Ganji V, Zhang X, Shaikh N, et al. (2011) Serum 25-hydroxyvitamin D concentrations are associated with prevalence of metabolic syndrome and various cardiometabolic risk factors in US children and adolescents based on assay-adjusted serum 25-hydroxyvitamin D data from NHANES 2001–2006. Am J Clin Nutr 94, 225–233.
749Pittas AG, Harris SS, Stark PC, et al. (2007) The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 30, 980–986.
750Tasinato A, Boscoboinik D, Bartoli GM, et al. (1995) d-alpha-tocopherol inhibition of vascular smooth muscle cell proliferation occurs at physiological concentrations, correlates with protein kinase C inhibition, and is independent of its antioxidant properties. Proc Natl Acad Sci U S A 92, 12190–12194.
751Witham MD, Crighton LJ, Gillespie ND, et al. (2010) The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ Heart Fail 3, 195–201.
752Zittermann A, Frisch S, Berthold HK, et al. (2009) Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 89, 1321–1327.
753Palmieri VO, Grattagliano I, Portincasa P, et al. (2006) Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. J Nutr 136, 3022–3026.
754Sargeant LA, Wareham NJ, Bingham S, et al. (2000) Vitamin C and hyperglycemia in the European Prospective Investigation into Cancer – Norfolk (EPIC-Norfolk) study: a population-based study. Diabetes Care 23, 726–732.
755Will JC & Byers T (1996) Does diabetes mellitus increase the requirement for vitamin C? Nutr Rev 54, 193–202.
756Ford ES, Mokdad AH, Giles WH, et al. (2003) The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey. Diabetes 52, 2346–2352.
757Aasheim ET, Hofso D, Hjelmesaeth J, et al. (2008) Vitamin status in morbidly obese patients: a cross-sectional study. Am J Clin Nutr 87, 362–369.
758Canoy D, Wareham N, Welch A, et al. (2005) Plasma ascorbic acid concentrations and fat distribution in 19,068 British men and women in the European Prospective Investigation into Cancer and Nutrition Norfolk cohort study. Am J Clin Nutr 82, 1203–1209.
759Devaraj S, Li D & Jialal I (1996) The effects of alpha tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin 1 beta secretion, and monocyte adhesion to endothelium. J Clin Invest 98, 756–763.
760Cominacini L, Garbin U, Pasini AF, et al. (1997) Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Radic Biol Med 22, 117–127.
761Devaraj S & Jialal I (1999) Alpha-tocopherol decreases interleukin-1 beta release from activated human monocytes by inhibition of 5-lipoxygenase. Arterioscler Thromb Vasc Biol 19, 1125–1133.
762Cooney RV, Franke AA, Harwood PJ, et al. (1993) Gamma-tocopherol detoxification of nitrogen dioxide: superiority to alpha-tocopherol. Proc Natl Acad Sci U S A 90, 1771–1775.
763Christen S, Woodall AA, Shigenaga MK, et al. (1997) gamma-Tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-tocopherol: physiological implications. Proc Natl Acad Sci U S A 94, 3217–3222.
764Handelman GJ, Machlin LJ, Fitch K, et al. (1985) Oral alpha-tocopherol supplements decrease plasma gamma-tocopherol levels in humans. J Nutr 115, 807–813.